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ABSTRACT
Psoriasis is a chronic inflammatory, immune-mediated skin condition that affects 
in average 2 to 3% of the world population, phenotypically characterized by red 
and scaly plaques on the skin of affected patients. It is a multifactorial disorder, 
in which both genetic predisposition and environment play key roles. Psoriasis 
lesional skin is characterized by abnormal keratinocyte differentiation and pro-
liferation, as well as dermal immune cell infiltration. Psoriasis is associated with 
several comorbidities, e.g. arthritis, however, currently no biomarkers exist that 
could be used to predict or identify these at an early stage. Many studies aimed to 
characterize the psoriasis transcriptome, but few studies have been focusing on 
elucidating the gene alterations in keratinocytes in this disease. In this thesis, we 
explored the transcriptomic landscape of epidermal cells from lesional and non-
lesional skin of patients with psoriasis, as well as from healthy volunteers’ skin 
and investigated the biomarker-potential of circulating microRNAs. 
In our first study, we investigated the alterations of the protein-coding transcrip-
tome in the psoriasis epidermal compartment. The separation of the epidermis from 
the dermis and sorting for CD45-neg cells allowed us to exclude dermal signatures 
including those from fibroblasts, endothelial cells, dendritic cells and T cells, but 
also from immune cells infiltrating the epidermis, known to populate at increased 
ratio the psoriasis lesional skin. We have identified biological pathways related to 
immune responses, cell cycle and keratinization involved in the epidermal altera-
tions, as well as the enrichment and dominance of psoriasis-associated cytokine 
signatures. Moreover, we established that genetic variations associated with pso-
riasis may contribute to the keratinocyte transcriptomic changes in the disease.
In our second study, we investigated the alterations of the non-protein-coding 
transcriptome in psoriasis and identified a set of long non-coding RNAs differ-
entially expressed in psoriasis epidermal cells. Several had genomic localization 
overlapping psoriasis-associated SNPs, suggesting their potential implication in 
the genetic susceptibility to psoriasis. We validated the over-expression of the 
lncRNA LINC00958 in CD45-neg cells from psoriasis lesions compared to non-
lesional and healthy skin and determined its expression in different skin cell types 
and subcellular localization.
In our third study, we focused on psoriatic arthritis, the major psoriasis comor-
bidity, affecting about 1/3 of the patients with cutaneous psoriasis. In particular, 
we investigated the potential of circulating microRNAs as biomarkers for early 
diagnosis of psoriatic arthritis symptoms in patients with cutaneous psoriasis. 
We have identified two circulating microRNAs, let-7b-5p and miR-30e-5p, with 
significantly reduced levels in plasma-derived extracellular vesicles of patients 
with confirmed psoriatic arthritis, compared to cutaneous-only psoriasis patients.
Finally, in our fourth study, we investigated the role and functions of miR-378a, 
previously found overexpressed in psoriasis lesional keratinocytes compared to 
non-lesional and healthy skin. In vivo, in a mouse model of psoriasis-like skin 
inflammation, the injection of miR-378a resulted in increased clinical signs of 
inflammation, increased skin thickness and number of proliferating cells in the 
epidermis. In vitro, in cultured primary human keratinocytes, miR-378a overex-
pression enhanced the expression of pro-inflammatory chemokines CXCL8/IL8 
and CCL20, as well as reduction of NFKBIA proteins levels.
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11 INTRODUCTION
“The finest clothing made is a person’s own skin, but, of course, society demands 
something more than this” - Mark Twain.
Between us and the rest of the word there is an interface that makes up about 16 
percent (~1/7th) of the total body weight: the skin. Largest organ in our body, it 
accounts for way more functions than just holding our organs inside. Its surface 
protects, regulates and senses the surrounding environment and it processes hun-
dreds to thousands physical sensations every day.
Many skin conditions could arise from anything that irritates, clogs or inflames the 
skin, provoking symptoms such as burning, swelling, itching and redness. These 
environmental factors, combined with specific genetic predisposition, might result 
in an inadequate immune response. If not quickly rebalanced, this can escalate into 
cancer-formation, pathogens’ infection, autoimmunity and prolonged inflammation 
that damages healthy cells. All these, not only can afflict the skin’s appearance 
but also, most critically, endanger people’s lives.
This thesis summarizes the effort made to further elucidate the transcriptomic 
changes that shape the transformation of keratinocytes in psoriasis lesions. We 
profiled protein-coding genes, as well as microRNAs and long non-coding RNAs, 
in isolated cells from the epidermis of patients with psoriasis, with the hope that 
one day some of these could be implemented in RNA-targeted therapies of psoriasis 
itself. Moreover, we screened for circulating microRNAs as potential biomarkers 
to easily diagnose psoriatic arthritis in patients with psoriasis. This would lead to 
timely treatments of patients at risk, promptly reducing the severity of the symp-
toms and improving their overall quality of life.
1.1 The Skin
The skin protects the body against infection, extreme temperatures, external trau-
mas, irritation and UV radiation, maintaining the balance of fluids and synthesiz-
ing vitamin D, functioning in this way as a physical, chemical and immunological 
barrier [1-3]. In just a square centimeter of skin we can find millions of cells and 
nerve endings that allow to sense the outside world, while its sweat glands and 
blood vessels help maintain a proper temperature and communicate about health 
and emotions, through events like blushing, flushing and sweating. Skin accounts 
for about 3 to 5 kilograms of our body weight and, although just few millimeters 
thick (from the thinnest on the eyelids to the thickest of palms and soles), if it 
could be spread out it would measure up to two square meters [2]. It comes in lots 
of different pigmentations and together with hair, nails, and specialized sweat and 
2sebaceous glands, skin forms the integumentary system. The key to the integu-
mentary system is layers: the skin has three main layers, from the outermost to the 
innermost represented by epidermis, dermis and hypodermis, each with particular 
types of cells that have specific functions (Figure 1).
Figure 1. The structure of the skin. Access for free at https://openstax.org/books/anat-
omy-and-physiology/pages/1-introduction Copyright© Jan 16, 2020 OpenStax. Creative 
Commons Attribution 4.0 International License.
1.1.1 The Epidermis
Assuming the skin is intact, the epidermis is the only layer visible. It’s made of 
keratinized, stratified squamous epithelial tissue – multiple layers (from four to 
five depending on the body location) set on top of each other, like bricks – which 
is composed of more than 90% of keratinocytes and the remaining of melanocytes, 
immune cells such as T lymphocytes and Langerhans cells and Merkel cells [2, 3]. 
The epidermis itself is composed of multiple layers (Figure 2), further described 
from the outside inwards. Stratum corneum, the main component of the skin bar-
rier is the one facing the surface of the skin. It is made of about 15 to 30 sheets of 
dead keratinocyte cells which undergone keratinization (or cornification), and it 
offers basic protection from pathogens and other environmental threats. In addi-
tion, at this level lipid chains contribute to the physical barrier formation too, 
preventing the dehydration of underlying tissues. Stratum lucidum - also known as 
3“clear layer”- consists of few rows of flat, dead keratinocytes that are only found 
in the thick skin of palms, soles and digits. The high content of clear proteins rich 
in lipids called eleidin, fills these cells providing their translucid appearance and 
creating a hydrophobic barrier. The Stratum granulosum, or “granular layer”, 
contains living keratinocytes, which have markers for late differentiation stage 
(involucrin, loricrin, filaggrin). It is called granular layer because the cells here 
get compressed and flattened, maturing as they move up through the epidermal 
layers. The membrane of the cells thickens and they start producing a fibrous 
structure called keratohyalin rich in histidine and cysteine proteins. The two major 
constituents of the keratohyalin are the profilaggrin (precursors of filaggrin) and 
the involucrin proteins. The first is responsible for binding the filaments of keratin 
together [4], while the second for building of the cells’ envelope in the cornified 
layer [5]. Moving towards the Stratum spinosum, or “spiny layer”, we reaching 
a point where cell regeneration, or mitosis, is active. Made of eight to ten layers 
of keratinocytes, cells here look spiny when they’re dehydrated for microscope 
slide preparation and that’s because they contain filaments that help them hold to 
each other called desmosomes. Another cell type we can find in this layer is the 
Lagerhans cell, tissue resident dendritic-cells which role is not fully understood yet 
but they’re thought to be protectors of the skin by processing microbial antigens 
and act as antigen-presenting cells [6]. Finally, the deepest, thinnest epidermal 
level is the Stratum basale or “basal layer” (also known as stratum germinati-
vum). It’s just a single layer of cuboidal-shaped cells representing the precursors 
of keratinocytes, where most of the new-cell production occurs. In this layer, two 
other important cell types can be found: Merkel cells, overrepresented on hands 
and feet skin surfaces, with the main responsibility of translating the “touch” sen-
sation to the brain through activation of sensory nerves; and the melanocytes, cells 
that produce melanin, a pigment that color hair and skin and protects the genomic 
content from being damaged by UV radiation. This stratum is also what connects 
the epidermis to the basal lamina, bellow which lie the other layers of the skin, 
the dermis and hypodermis [1, 7, 8].
4Figure 2. Layers of the epidermis. Access for free at https://openstax.org/books/anatomy-
and-physiology/pages/1-introduction Copyright© Jan 16, 2020 OpenStax. Creative 
Commons Attribution 4.0 International License.
1.1.1.1 Keratinocytes
The bulk of epidermis is made of cells called keratinocytes (KCs), which are the 
building blocks of that tough, fibrous protein keratin that gives structure, durability, 
and waterproofing to hair, nails, and outer skin. These cells are constantly dying and 
being replaced -- millions of them every day are lost, enough to completely replace 
the epidermis every 4 to 6 weeks [9]. Keratinocytes are encoded to undergo an event 
called “terminal differentiation”, a type of controlled programmed journey, which 
slowly takes place as the keratinocytes moves up through all layers of epidermis. 
During this process of differentiation, the keratinocytes make multiple changes 
in both its morphology and function, until they reach the surface. The epidermal 
differentiation program is regulated at several levels including signaling pathways, 
transcription factors, and epigenetic regulators that establish a well-coordinated 
process of terminal differentiation [10]. As the basal keratinocytes move upward 
the keratin intermediate filament structures formed by keratin 5 (K5) and keratin 
(K14) is replaced by keratin 1 (K1) and keratin 10 (K10) filaments, the markers of 
early differentiation that start to get expressed at the suprabasal layer [8, 11, 12].
51.1.2 The Dermis
The dermis, just below the epidermis, is composed of two layers [13]. The upper 
papillary layer is composed of a thin sheet of areolar connective tissue that is rid-
dled with little peg-like projections called dermal papillae. Just below, we find the 
deeper and thicker reticular layer, which makes up 80 percent of the dermis, made 
of dense irregular connective tissue. All of the dynamic parts contained within 
the dermis –like blood vessels (capillaries), collagen, elastic fibers, and extrafi-
brillar matrix – are distributed between both its layers. The dermis is responsible 
for the elasticity and resilience of the skin and the presence of mechanoreceptors 
and thermoreceptors provides respectively the sense of touch and heat. Cells here 
are characterized by a reduced ability to regenerate, resulting in a more difficult 
healing from wounds. The dermal dense extracellular matrix (ECM) is populated 
primarily by sparsely distributed fibroblasts, but other cell types are also found, 
including Schwann cells, macrophages, mast and stem cells [14].
1.1.3 The Hypodermis
The most basal layer of the skin is the subcutis or hypodermis. It consists of mostly 
adipose (or fatty) connective tissue and it provides insulation, energy storage, 
shock absorption, and helps anchor the skin. Drugs are commonly injected in this 
layer due to the high vascularity of the tissue which allows a fast absorption of the 
drug itself [15]. Adipose tissue can contribute to immune response and the role of 
adipocytes has been shown to be relevant for epidermal homeostasis during hair 
follicle regeneration and wound healing [16-18].
1.1.4 Skin Immune Cells
The skin represents the primary mechanical and immunological barrier with features 
that protect us from microbial pathogens’ penetration and physical insults. It also 
represents an exclusive environment in which skin cells interact with the immune 
cells for the maintenance of the body’s homeostasis and, in certain cases, induc-
ing immune responses [19, 20]. Heterogeneous and highly specialized immune-
resident cells and immunocompetent skin-trophic lymphocytes that cooperate to 
create a network in the skin, establishing what was previously known as SALT 
(skin-associated lymphoid tissue), successively renamed as SIS (skin immune 
system) [3, 21-23].
In the epidermis, a specific subset of dendritic cells (DCs), the antigen-presenting 
Langerhans cells, project their dendrites toward the epithelial layer and sample 
bacterial antigens such as toxins [6]. These can function as anti-inflammatory and 
activator of the inflammation depending on the context. In the dermis, the den-
dritic cells have higher efficiency in detecting dead cells and presenting antigens 
6such as viruses, other intracellular pathogens and/or skin associated self-antigens 
to T cells [24]. If the dendritic cells are considered the immune system sentinels, 
T cells are the immune system effectors. 
Healthy skin presents more than twice the number of T cells which are found in 
the blood [25]; most of them are considered memory T cells which have previ-
ously encountered antigens and, therefore, can rapidly reactivate. T cells in the 
epidermis are mainly CD8+ T cells, a subtype that can become cytotoxic and kill 
target cells upon their activation [26]. Their prolonged permanence in the epider-
mis is mostly disconnected from the circulation [27]. In contrast, in the dermis 
there are mainly CD4+ T cells, with a predominant modulatory role in the immune 
response. Even in healthy non inflamed skin, beside dendritic cells, the dermis 
contains other types of immune cells such as, ab T cells, gd T cells, natural killer 
(NK) cells, B cells, mast cells, and macrophages, which can be involved in the 
allergic reaction of the skin [2].
Skin dendritic cells and keratinocytes can sense tissue damage derived from dif-
ferent sources (i.e. wounds), through evolutionary conserved receptors that rec-
ognize pathogen derived molecular patterns or host derived molecules that have 
been exposed by cell death (i.e. DNA) [28, 29]. The activated dendritic cells 
migrate to the lymph nodes where they present antigens to naïve T cells, prepar-
ing them to differentiate into effector T cells (process known as “sensitization”) 
[30]. These activated T cells can then migrate towards the epidermis and suppress 
the affected keratinocytes to control the infection or secrete signals that recruit 
additional immune effector cells [31]. The immune response operated by helper 
T lymphocytes including Th1 (T-helper cell type 1) cells, is followed by the pro-
duction and release of type II interferons (IFNs) such as IFN-γ, by Th2 releasing 
IL-4, IL-5 and IL-13 and by the more recently discovered T-helper cells Th17 with 
their production of IL-17 and IL-22 and Th22, producing IL-22, IL-13, TNF-a 
and FGF-b (Figure 3) [32-34]. Further insights about these cells in the psoriasis 
context will be provided later.
7Figure 3. Profile of T helper lymphocytes, polarization from naïve to more specialized, and 
related cytokines production. Reproduced and adapted with permission from Quaresma 
JAS, 2019. Copyright© 2019 American Society for Microbiology.
Keratinocytes, in addition to provide a physical barrier, they are the first line 
of immunological defense in the skin. They can recognize pathogens through 
pathogen-associated molecular patterns (PAMPs) via their pattern recognition 
receptors (PRRs) such as Toll-like receptors (TLRs) -expressed on both their cell 
surface (TLR1, 2, 4 and 5) and on endosomes (TLR3, 9)- and nucleotide-binding 
oligomerization domain (NOD)-like receptors (NLRs) [2, 35-37]. Upon pathogen 
recognition or under specific inflammatory conditions, keratinocytes produce 
chemokines and cytokines such as CXCL1-5, CXCL8 (IL-8), IL-1, IL-6, IL-10, 
IL-17C, IL-22, IL-18, IL-36 and TNF-a, as well as defensive antimicrobial factors 
including b-defensins, LL37 and S100 proteins [2, 38-41]. Release of inflamma-
tory mediators such as IL-1 by keratinocytes induce the activation of dendritic 
cells, while chemokines (i.e. the chemotactic factor CXCL8/IL-8) recruit primarily 
neutrophils, but also macrophages and T cells [42, 43].
Other cells have fundamental roles in the intricate organization of the skin immune 
complex. 
8Neutrophil granulocytes, the most abundant immune cells, in situations of injury 
or infection travel through blood vessels and capillaries attracted by chemokines 
through chemotaxis [44], and communicate with antigen-presenting cells (APCs) 
where the inflammation takes place [45]. They participate in removing foreign 
particles or pathogens through processes of phagocytosis and endocytosis, as well 
as amplify inflammatory responses by releasing large quantities of antimicrobial 
proteins (AMPs) [46, 47].
Eosinophils, granulocytes originated in the bone marrow, are recruited by Th2-
cytokines in the latest stages of the inflammatory reaction. These contains granules 
with toxic arginine-rich proteins and are sources of a large variety of cytokines such 
as TGF-α, TGF-β, IL-13, and VEGF, contributing to tissue healing in case of inju-
ries and tissue remodeling and angiogenesis in case of chronic inflammation [48].
Basophils, which have a relatively short life span (1-2 days), are developed in 
response to cytokines such as IL-3, IL-4, IL-33 and IL-8 and their infiltration 
in the skin occurs often together with eosinophils, in a ratio that can differ [49]. 
Presence of immunoglobulin type E (IgE) receptors on their surface makes them 
suitable in skin immunity to fight infectious or dangerous agents [50]. 
Macrophages in the skin play important roles in different stages of wound repair 
and tissue regeneration, with the ability to migrate towards lymph nodes in par-
ticular immunologic situations. Moreover, they regulate processes involving skin 
homeostasis, inflammation, autoimmunity and skin cancer [51]. Recently, a newly 
discovered subset of nerve-associated macrophages has been shown to take part 
in the nerves’ regeneration process after an injury [52].
Mast cells are very similar to the basophils in terms of mechanism of action and 
type of mediators but are predominantly found in tissues instead of circulating 
in the blood stream [53]. Activated by inflammatory peptides released by nerve 
fibers, mast cells establish with these a feedback mechanism that gives raise to 
pain and itch [54].
Natural Killer (NK) and Natural Killer T (NKT) cells, after being exposed to 
the cytokine IL-12, they activate, mature and produce consistent volumes of IFN-g 
[55]. NK cells are fundamental components of the innate immune system, while 
NKT have a role in both innate and acquired immune response, besides promoting 
the differentiation and enhancing the biological features of NK cells [56]. After 
infiltrating the skin, NKT cells can behave in different ways, either stimulating 
or suppressing the immune system [57].
9Innate lymphoid cell (ILCs), class of immune cells recently identified in skin, 
which shares transcription factors (TFs) and cytokine profile similarities with T 
cell subsets but don’t seem to have antigen-specific receptors on their surface [58]. 
ILCs quickly respond to infections, they control skin homeostasis and responses 
of the adaptive immune system, being categorized into three subgroups named 
ILC1 (adaptive response mediated by Th1 cells), ILC2 (adaptive response medi-
ated by Th2 cells) and ILC3 (adaptive response mediated by Th17 cells) [59, 60].
B lymphocytes, which main function is to secrete the proteins that are bound to 
their membrane, known as antibodies (Ab) or immunoglobulins (Ig). Members of 
the TNF (tumor necrosis factor) ligand family promote the activation and develop-
ment of B cells into mature B lymphocytes [61]. These play a significant role in 
systemic autoimmune diseases but they can also present autoantigens or promote 
the interruption of peripheral T-cells tolerance [23]. 
Endothelial cells, present in the vascular and lymphatic systems of the skin, have 
the ability to regulate different adhesion molecules such as intercellular adhesion 
molecules-1 (ICAM-1), endothelial-leukocyte adhesion molecule-1 (ELAM-1) 
and the vascular cell adhesion protein VCAM-1, in response to stimuli from 
TNF-a [23, 62]. Endothelial cells prevent the formation of blood clots (thrombi), 
permeabilize the blood vessels controlling the blood pressure, they are involved 
in tissue aging, presentation of antigens, process of wound repair and formation 
of blood vessels from pre-existing vasculature (angiogenesis) [63].
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Table 1. Immune role of skin cells.
Cell Location(s) Function(s) Activating factors
Cytokine(s) 
produced
Keratinocyte Epidermis
Mechanical barrier, kera-
tin production, immune 
function, innate immunity
IFN-γ, infections
IL-1, IL-6, IL-10, 
IL-12, IL-15, IL-18, 
IL-19, IL-20, CCL20, 
CXCL8/IL-8, 
CXCL9, CXCL10, 
CXCL11, TNF-
a, TGF-β, IL-23, 
GM-CSF, G-CSF
Langerhans 
cell Epidermis
Antigen-presenting cell, 
migration and recruit-
ment to the secondary 
lymphoid organs, and 
antigenic presentation to 
T lymphocytes
Infectious and 
noninfectious 
antigens
IL-12, IL-23, IL-6, 
TNF-a
Dermal 
dendrocyte Dermis
Antigen-presenting cell, 
phagocytosis, regulation 
of collagen synthesis, and 
homeostasis of the dermis
Infectious and 
noninfectious 
antigens
IL-12, IL-23, IL-6, 
TNF-a
Plasmocytoid 
dendritic cell Dermis Antigen-presenting cell
IL-3, CD40, virus, 
bacterium, CpG 
oligonucleotides
IL-12
Inflammatory 
dendritic cell
Dermis, 
epidermis Antigen-presenting cell
Microbial and 
endogenous 
antigens
IL-12
T CD4 Th1 cell
Mainly in 
the dermis; 
rare in the 
epidermis
T helper lymphocyte; 
coordinates immune 
function
IL-12 IFN-γ
T CD4 Th2 cell Dermis; rare in epidermis
T helper lymphocyte; 
coordinates immune 
function
IL-4 IL-4, IL-5, IL-13
T CD4 Th3 cell Dermis
T helper lymphocyte; 
coordinates immune 
function
IL-4, IL-10, 
TGF-β IL-4, IL-10, TGF-β
T CD4 Th9 cell Dermis
T helper lymphocyte; 
coordinates immune 
function
IL-4, TGF-β IL-9, IL-10, IL-21
T CD4 Th17 
cell Dermis
T helper lymphocyte; 
coordinates immune 
function
IL-6, IL-1, IL-23 IL-17, IL-22
T CD4 Th22 
cell Dermis
T helper lymphocyte; 
coordinates immune 
function
TNF-a, IL-6 IL-22, FGF-β, IL-13, TNF-α
T CD4 Th25 
cell Dermis
T helper lymphocyte; 
coordinates immune 
function
IL-25, Act1 IL-4, IL-13, IL-25, Act1
Treg cell Dermis Control of the immune response IL-2, TGF-β IL-10, TGF-β
T CD8 cell Dermis, epidermis
Elimination of intracel-
lular microorganisms and 
infected cells
IL-2, IL-12, IFN 
type I IFN-γ
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T  gd cell Dermis
Elimination of intracel-
lular microorganisms and 
infected cells; cell death
IL-2, IL-12 IL-17, IFN-γ
NKT cell Dermis Elimination of lipid antigens IL-12, IL-18 IL-4, IL-17, IFN-γ
NK cell Dermis
Innate immunity against 
viruses and intracellular 
bacteria
IL-12, IL-15 IFN-γ
ILC Dermis Innate immunity
IL-12, IL-18, 
IL-23, IL-25, 
IL-33, TGF-β
IL-1, IL-23, IL-25, 
IL-33, TSLP
B cell Dermis Humoral immune response
IL-2, IL-4, IL-6, 
IL-11, IL-13, 
TNF-α, BAFF
Antibodies
Plasma Dermis Synthesis and release of antibodies
IL-4, IL-6, IL-10, 
IFN-γ, BAFF Antibodies
Breg cell Dermis Control of the immune response IL-2, IL-4, IL-5 IL-10, TGF-β
M1 
macrophage Dermis
Phagocytosis, antigen 
presentation, bactericidal 
action
IFN-γ IL-6, IL-12, TNF-α, iNOS
M2 
macrophage Dermis
Phagocytosis, antigen 
presentation, regenerative 
effects
IL-4, IL-13 IL-10, TGF-β, arginase-1
Mast cell
Dermis 
around the 
vessels
Hypersensitivity reaction, 
vasodilation, chemotaxis, 
inflammation
IL-3, IL-5, IL-13
TNF-α, IL-1, IL-4, 
IL-5, IL-6, IL-13, 
CCL3, CCL4, IL-3, 
GM-CSF
Basophil Dermis
Hypersensitivity reaction, 
vasodilation, chemotaxis, 
inflammation
IL-3, IL-5, 
GM-CSF, hista-
mine releasing 
factor
IL-4, IL-13
Eosinophil Dermis
Hypersensitivity reaction, 
vasodilation, chemot-
axis, inflammation, IgE 
production
IL-5, IL-13, 
GM-CSF
IL-3, IL-5, IL-8, 
IL-10, leukotrienes, 
GM-CSF, hydrolases
Neutrophil Dermis, epidermis
Innate immunity, 
phagocytosis
C3, IFN-γ, TNF-
α, GM-CSF
ROS, proteolytic 
enzymes
Endothelial 
cell Dermis
Inflammation, immune 
response, infections IL-1, IL-6, TNF-α
TNF-α, IL-1, IL-6, 
IL-8, IL-15, IL-17, 
IL-18, G-CSF, 
GMCSF, VEGF
Fibroblast Dermis Inflammation, immune response, infections IL-1, TNF-α
PGE2, GM-CSF, 
CXCL8/IL-8, MIP-
2, PDGF, TGF-β, 
FGF-β
Reproduced and adapted with permission from Quaresma JAS, 2019. Copyright© 2019 
American Society for Microbiology.
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1.1.5 NF-kB Signaling Transduction
In both immune and non-immune cells, the NF-kB signaling pathway has been 
found to play substantial roles in homeostasis regulation and promotion of inflam-
mation. The basic components of this pathway include receptors (pro-inflammatory 
cytokines such as TNF-a and IL-1), signal adapters (TNF receptor associated fac-
tors –TRAFs and receptor interacting proteins –RIPs), IKK complexes (IKKa or 
IKK1, IKKb or IKK2 and IKKg or NEMO), IkB proteins (IkBa, IkBb, IkBz, IkBe, 
BCL-3, p100 (precursor of p52), p105 (precursor of p50)) and NF-kB dimers (p50 
(NF-κB1), p52 (NF-κB2), p65 (RelA), c-Rel and RelB) [64-66]. In homeostatic 
conditions, homodimers and heterodimers are kept inactivate in the cytoplasm of 
the cells, associated to the inhibitory proteins IkB. When cells receive intra- and 
extra-cellular stimuli, the IKK complexes are activated, resulting in phospho-
rylation and ubiquitination of IkB proteins that, in turn, are degraded and NF-kB 
dimer released. Upon further post-translational modifications, the NF-kB dimer is 
transported to the nucleus, where it can finally bind to its target genes and promote 
their transcription [67, 68]. This summarizes the canonical (or classical) pathway 
of NF-kB, which results in the mechanism of signal transduction. Alternatively, 
in response to a subset of tumor necrosis factor (TNF) family members such as 
CD40L, BAFF, LTB, RANKL and TWEAK, the NF-κB-inducing kinase NIK 
activates IKKa, which in turn phosphorylates p100, precursor of p52. Activated 
p52 forms a heterodimer with Rel-B and the complex RelB/p52 translocate into 
the nucleus of the cell, inducing the expression on non-canonical NF-κB related 
genes, such as the anti-apoptotic genes Bcl2 and Bcl-xl (involved in B cell matu-
ration and survival), promoting cell survival [69-71].
In general, a dysregulation of the immune responses cause skin disorders such 
as psoriasis [72-74], atopic dermatitis [75, 76], cancers [77, 78] and many other 
skin related diseases.
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1.2 Psoriasis
Psoriasis is a common immune-mediated skin disease with a strong genetic back-
ground, which affects approximately 0.5%–1% of children and 2-3% of the adult 
population (>125 million people worldwide) [79], reported at higher rates in loca-
tions distant from the equator [80] and for which there is no clear cause or cure. 
Psoriasis may begin at any age, however, there are two peaks: at 20-30 years and 
50-60 years. This means that 50% of the cases in psoriasis starts before the age 
of 25 [81]. Psoriasis is recognized as a skin disease with significant impact on 
quality of life and emotional well-being of patients suffering from it [82]. Indeed, 
depression is very common among these patients [83]. It waxes and wanes through-
out the life of a patient, and without treatment a spontaneous remission is highly 
unlikely [84]. Although the exact etiology of psoriasis is unknown, it is a widely 
held view that can be provoked by non-specific triggers such as mild trauma, 
drugs (lithium, interferon-alpha, antimalarial medications etc.), stress (which is 
probably the strongest environmental trigger of psoriasis) but also viral infections 
(e.g. HIV) can start the inflammatory processes which lead to the development 
of the disease [85]. This chronically relapsing inflammatory disease is thought 
to be multifactorial, involving both environmental and genetic factors [86, 87]. 
It is characterized by aberrant interaction between keratinocytes and infiltrating 
immune cells, which leads to hyperproliferation and altered differentiation of the 
keratinocytes themselves and formation of psoriatic plaques [88, 89]. The severity 
of the psoriatic plaques is quantified by two major scoring systems: the psoriasis 
area and severity index (PASI) and the physician’s global assessment (PGA). In 
addition, the Dermatology Life Quality Index (DLQI) represents a ten-question 
questionnaire which assesses how psoriasis is affecting well-being and quality of 
life of psoriasis patients [90].
The characteristic histological features of psoriasis are epidermal hyperplasia and 
an inflammatory cell infiltration in both the dermis and the epidermis. The rapid 
proliferation of immature keratinocytes in psoriasis, which may increase more 
than ten times over the normal rate, is combined with an impaired cellular differ-
entiation, while the retention of the keratinocytes’ nuclei in the stratum corneum 
results in a phenomenon called “parakeratosis” [91] (Figure 4). Keratinocytes, 
once activated by different triggers (environment, injuries, stress, cytokines, viral 
infection etc.), have been shown to produce a large number of cytokines, which 
may induce further proliferation of these cells and have other pro-inflammatory 
and immunomodulatory effects [92, 93].
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Figure 4. Normal skin vs. established psoriasis; both the diagrams (upper) and the histol-
ogy (bottom) illustrate increased epidermal thickness and dermal lymphocyte infiltration. 
Reproduced and adapted with permission from “An Atlas of Psoriasis, Second Edition - 
2004” by Lionel Fry (upper) (Copyright© 2004 Taylor & Francis Group) and Michigan 
Medicine (bottom) Copyright 2020 Regents of the University of Michigan.
1.2.1 Psoriasis clinical presentation
Psoriasis can manifest as various phenotypes clinically (Figure 5). The most com-
mon subtype – about 85-90% – is the chronic plaque-type psoriasis (also known 
as psoriasis vulgaris), red scaly plaques on scalp, knees and elbows. The guttate 
psoriasis, counting for the 10%, it’s an interesting subtype which differs not in the 
aspect but in its course: many little red spots that can be spread along the whole 
body, which can spontaneously (or with the help of some treatments) heal and in 
many cases never come back. Inverse psoriasis (<5%), which does not manifest 
scaly plaques but just red patches on the skin folds (inguinal area, armpit, inter-
gluteal, etc.) and differentiate it from candidiasis it is often challenging. Pustular 
psoriasis, which includes palmoplantar pustulosis, acrodermatitis continua of 
Hallopeau and generalized pustular psoriasis, is characterized by blisters filled 
with pus and broad areas of red, inflamed skin. Finally, the erythrodermic psoria-
sis (1% to 2% of all cases) can involve up to 90% of the whole body and has the 
typical sunburn looking pruritic and inflamed skin [85, 94, 95].
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Figure 5. Clinical features of psoriasis (PsO) –pictures of psoriasis subtypes and their 
body location. Reproduced and adapted with permission from Lionel Fry, 2004, “An Atlas 
of Psoriasis” Second Edition. Copyright© 2004 Taylor & Francis Group.
1.2.2 The genetics of psoriasis
Psoriasis has a strong genetic background. Results from twin and population studies 
have shown higher incidence of psoriasis (either vulgaris or psoriatic arthritis) in 
monozygotic rather than in dizygotic twins (probandwise concordance rate of 0.33 
in monozygotic vs 0.17 dizygotic) [96, 97] and in first- and second-degree rela-
tives of patients than in the general population [88, 98-100]. Linkage and genetic 
association studies comprising large case-control datasets revealed potential can-
didate susceptibility variants known as single nucleotide polymorphisms (SNPs) 
which are linked to psoriasis [101-104]. The allele HLA-C*06:02 is considered 
the major genetic determinant of psoriasis [105-107]. It is present in the psoriasis 
susceptibility-1 (PSORS1), a region that includes genes in the major histocompat-
ibility complex (MHC). This contributes approximately to 40-50% of the psoriasis 
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heritability and encode for human leukocyte antigens (HLAs) [105-110]. Regarding 
psoriatic arthritis, the most shared comorbidity among patients with psoriasis, it 
has been shown that HLA-B alleles are associated with higher risk of developing 
psoriatic arthritis; in particular HLA-B*27 [107, 111, 112], while HLA-C*06:02 
has lower association risk to this comorbidity [111]. 
Approximately 36 genomic susceptibility loci have been associated with psoriasis, 
some of them (PSORS1, PSORS2 and PSORS4) giving higher contribute to the 
disease than the others [105, 113, 114]. Mutations of the gene CARD14, localized in 
the PSORS2 region on chromosome 17 (17q25.3), are responsible for the enhanced 
pro-inflammatory effect of NF-kB and overexpression of genes in keratinocytes 
which have been associated to psoriasis [115-117]. However, despite the proven 
genetic predisposition in psoriasis, the link between environmental triggers, gene 
expression alterations and genetic heterogeneity is not clear yet [118]. The major-
ity of susceptibility genes identified in genome-wide association studies (GWAS) 
are related to adaptive immunity (cytokines, cytokine receptors and inflammatory 
pathways), while some are related to innate immunity, keratinocyte functions and 
skin barrier, suggesting that the genetic predisposition involves both the skin and 
the immune system [101, 102, 119]. One example for the skin-related genes are 
late cornified envelope (LCE) genes that are part of the epidermal differentiation 
complex (EDC) which is involved in the terminal differentiation of the epidermis 
[120, 121]. Meta-analysis studies reported an association between psoriasis and 
the common deletion LCE3C/LCE3B-del in the late-cornified envelope cluster, 
which is known to be on chromosome region 1q21.3, where the PSORS4 locus 
was identified [122, 123]. Since localized in the cornified layer of the epidermis, 
the assumption was that LCE genes encode for structural proteins involved in 
physical barrier function [8], even though other studies have provided hypothesis 
about their potential role as antimicrobial peptides [124].
1.2.3 Immunopathogenesis of psoriasis
Both the innate and the adaptive immune system play fundamental roles in the 
initiation and maintenance of psoriasis [125]. Immunologic changes are caused 
partially by the genes – since behind the skin inflammation in psoriasis, thousands 
of protein-coding genes are known to be differentially expressed – and partially 
by the environment.  One of the key participants in the innate immunity are the 
keratinocytes, which can respond to different danger signals and recruit T cells to 
the skin, which are important in sustaining disease activity [34, 38]. Keratinocytes 
produce AMPs such as LL-37, defensins, and S100 proteins and, once injured or 
subjected to inflammatory negative feedback from certain cytokines, they can pro-
duce high doses of the chemokine CCL20 and CXCL8/IL-8. CCL20 has the purpose 
to recruit myeloid dendritic cells (DCs) and Th17 cells into psoriasis skin, while 
IL-8/CXCL8 functions as chemoattractant for neutrophils to recruit them to the 
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site of the lesion [34, 38, 126, 127]. Fundamental transcription factors in psoriasis 
lesions are cyclic adenosine monophosphate (cAMP), Janus kinase (JAK), activator 
protein-1 (AP-1), CCAAT enhancer binding protein beta (C/EBP-b) and nuclear 
factor-κB (NF-κB). These enhance the expression of pro-inflammatory cytokines 
upon modulation of TNF-a and IL-17 production, sustaining the inflammation loop 
in the lesional epidermis of psoriasis patients [128, 129]. A simplified representa-
tion of the immunopathogenic mechanisms in psoriasis is illustrated in Figure 6.
1.2.3.1 Cellular and molecular immunologic circuits in psoriasis
From a general point of view, the model of pathogenesis of psoriasis starts with a 
genetically predisposed individual, which encounters one or many potential envi-
ronmental triggers inducing keratinocytes stress. It is known today that psoriasis is 
not exclusively a T cell-dependent disease but keratinocytes play a pivotal role in 
triggering the early stages of the pathogenesis and perpetuating the chronic inflam-
mation in psoriasis, in a mutual interaction with the T cells [34, 93, 130, 131]. 
Stressed keratinocytes begin to release self-DNA and self-RNA complexes into 
the extracellular compartment. Plasmacytoid dendritic cells (pDCs) are activated 
by these complexes and initiate the production of IFN-a [132]. The presence of 
IFN-a lead to the activation and maturation of dendritic cells (DCs) which cir-
culate in the lymph nodes where they present the putative antigen to the naïve T 
cells. Activated dendritic cells produce IL-23 and IL-12, which stimulates the three 
populations of CD4+ T-helper cells Th1 and Th17 [133]. IL-23 from inflammatory 
DCs activates Th17 cells to produce IL-17A and IL-17F, which drive keratinocyte 
responses [133-135]. Once activated, the epidermis can produce abundant cytokines 
and inflammatory mediators, including IL-8/chemokine CXCL8, MCP-1/CCL2, 
CXCL1, CXCL2, and CXCL3, and CCL20 [38, 88, 136]. These chemokines attract 
leukocytes such as neutrophils, DCs, and CCR6+ Th17 cells. CXCL9, CXCL10, 
and CXCL11 are also produced and they recruit additional circulating Th1 cells 
expressing CXC-chemokine receptor 3 (CXCR3+) and CC-chemokine receptor 4 
(CCR4+) and Th17 cells expressing CCR4 and CCR6 into the dermis and epider-
mis. T cell-derived cytokines act on epidermal keratinocytes as proximal inducers 
of these inflammatory circuits [3, 38, 88, 136].
1.2.3.2 Autoantigens and psoriasis autoimmunity
More recently, activation of autoimmune pathways in psoriasis has emerged. Prinz 
et al. in 2015 has proven that antigen-specific CD8+ T cell mediate autoimmune 
response against melanocytes, hypothesizing that psoriasis is an autoimmune disease 
that depends on HLA class I. In the study they show that the main psoriasis risk 
allele HLA-C*06:02 confers susceptibility to psoriasis by promoting melanocytes-
specific autoimmunity through presentation of ADAMTSL5 (ADAMTS Like 
5), autoantigen generated by ERAP1 (Endoplasmic Reticulum Aminopeptidase 
1). If an inflammatory trigger meets under pathogenic predisposition related to 
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gene variants from interferon signaling pathway, NF-kB activation pathway and 
others, then this would generate an increased inflammatory response, upregula-
tion of pro-inflammatory signals and ligands-dependent recruitment of immune 
cells. The CD8+ T cells that infiltrate the epidermis allow the recognition of the 
autoantigen ADAMTSL5, which increases the risk for psoriasis in epistasis with 
HLA-C*06:02 [137, 138].
Besides ADAMTSL5, also the antimicrobial peptide LL37 (alternatively known 
as CAMP) was found having increased expression in keratinocytes of psoriasis 
lesions as well as in psoriasis-associated immune cells (e.g. macrophages and 
dendritic cells) [139]. Moreover, LL37 has the ability to convert inert self-DNA 
into condensed structures complexed with AMPs, activating TLR9 that allows 
plasmacytoid dendritic cells sensing viral and microbial DNA (event that does 
not occur in normal conditions). This results in the production of IFN-a, which 
provides inner stimuli for dendritic cells and T cells, leading to the development of 
psoriatic plaques. Since this represents a unique inflammatory pathway, which is 
normally used in antiviral immune responses, LL37 has been proposed as psoriasis 
autoantigen, responsible of triggering the inflammatory feedback loop [140, 141].
Figure 6. The immunopathogenesis of psoriasis. Interplay of cutaneous cell types, which 
is dependent on macrophages, dendritic cells, T cells, and other cells of the immune sys-
tem, involves many cytokines and chemokines that orchestrate the pathological changes 
normal (left side) to psoriatic (right side) skin. Reproduced and adapted with permission 
from Greb, J. E., et al. (2016). “Psoriasis”. Copyright© 2016 Macmillan Publishers 
Limited, part of Spring Nature.
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1.2.3.3 Cytokine and chemokine imbalance in psoriasis
Cytokines such as IL-12 and IL-23, both released by dendritic cells and mac-
rophages, induce the polarization of several CD4+ T cells which, in turn, produce 
some of the most important cytokines in psoriasis: interleukin-17A (IL-17A) and 
IL-17F, interleukin (IL-22), interferon-gamma (IFN-g) and tumor necrosis factor-
alpha (TNF-α), [38, 136, 142]. IL-23 in particular, has been recognized as a key 
player in the pathogenesis of chronic autoimmune diseases [143] and has a special 
role in psoriasis, through activation of Th17 lineage followed by release of IL-17 
and IL-22 pro-inflammatory cytokines [144].
IL-17A is produced by CD4+ T cells which are polarized by IL-1b and IL-6 
cytokines into Th17 cells but also by the CD8+ T cells subset Tc17 [145]. It acts 
on keratinocytes leading to an increased expression of chemokines such as CCL20, 
CXCL1, CXCL3, CXCL5, CXCL6 and CXCL8 (IL-8), and it has been shown 
to play a role in recruiting myeloid dendritic cells, more T-helper 17 cells and 
neutrophils to the psoriatic lesion. IL-17A induces production of AMPs (such as 
b-defensin-2, S100 protein A7, A8, A9) and pro-inflammatory cytokines, as well 
as producing granulocyte colony stimulating factor (G-CSF). These, in turn, may 
help sustain immune responses in the skin, as well as inflammation and plaques 
development in psoriasis [38, 142, 146-148]. IL-17A has also the positive role in 
protecting skin from Staphylococcus aureus infections but also from gastrointesti-
nal infections due to Escherichia coli and activating immune response against the 
bacterium responsible for tuberculosis (Mycobacterium tuberculosis) and against 
fungal infections [149-151]. Therefore, excessive IL-17A-related inflammation 
that could lead to chronic inflammatory diseases and the absence or dysfunctional 
IL-17A due to therapies with specific blockers while the body is infected by patho-
gens, represent a balance between two conditions that requires fine regulation in 
order to maintain the overall epithelia homeostasis [152].
IL-17F (known also as CANDF6 or ML1), shares the same locus and receptors 
as IL-17A, having the highest homology to this cytokine, being co-regulated and, 
therefore, often co-expressed [153]. Although only one polymorphism (rs763780 
(His161Arg)) in the IL-17F gene has been recently associated to increased psoriasis 
susceptibility [154], high levels of IL-17F cytokine have been found in psoriasis 
lesional skin compared to non-lesional and healthy [155] as well as in the serum 
of the psoriasis patients [156]. In psoriasis-like model (imiquimod mice), IL17F 
has been found to promote skin inflammation upon infiltration of γδ T cells and 
RORγt+ innate lymphocytes [157].
Other members of the IL-17 family (Figure 7) include IL-17C which, together 
with IL-17A and IL-17F, has the highest expression in lesional skin of psoriasis 
patients [158], while IL-17B, IL-17D show reduced expression in psoriasis skin 
[155], most likely providing a minor contribution to the inflammation occurring 
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in psoriasis. Finally, IL-17E (also known as IL-25) is produced by several dif-
ferent cell types including epithelial and endothelial cells, T cells, macrophages, 
dendritic cells and type-2 myeloid cells. It’s upregulated in psoriasis skin lesions 
(produced by involved keratinocytes) but also atopic dermatitis and contact der-
matitis [159-162].
Figure 7. The IL-17 family members with respective receptors. Reproduced and adapted 
with permission from Brembilla NC et al., 2018; Frontiers in Immunology. Copyright© 
2018 Brembilla, Senra and Boehncke.
IL-22, member of the IL-20 family and produced by T-helper 22 cells (and in part 
by Th17 cells), it inhibits epidermal differentiation leading to a disturbed skin 
barrier and induces pro-inflammatory gene expression and migration of human 
keratinocytes. Binding its receptors IL-22R1/IL-10R2 it activates JAK/STAT3 
pathway, contributing to the stimulation of inflammatory responses [38, 136, 163-
165]. Moreover, the activation of this pathway by IL-22 leads to a reduction in 
the expression levels of keratinocyte differentiation markers such filaggrin (FLG), 
loricrin (LOR), involucrin (IVL) and class I/II cytokeratin members (CKs) such 
as keratin 1 (KRT1) and keratin 10 (KRT10) [165, 166].
IFN-g activates a signaling pathway that was considered to be the major player in 
the pathogenesis of psoriasis vulgaris [167]. Nowadays, IFN-g has been redefined 
21
as more relevant for the initiation phase of the disease [168] and its increased lev-
els in the serum of psoriasis patients has been proposed as a marker of diseases 
prognosis and severity [169]. It belongs to the interferon family type II and can 
be produced by T-helper 1 cells but also by T-helper 17 and NK cells [170-172]. 
Moreover, a population of T cells co-producing IL-17A and IFN-g was identified 
in psoriasis lesional skin [173]. Keratinocytes, which carry the IFN-γ receptor on 
their membrane, in presence of the ligand respond by originating inflammatory 
and anti-viral responses through the JAK1-2/STAT1 signaling pathway [174].
TNF-α, member of the TNF superfamily and mainly stored by activated mast cells 
and macrophages in the skin, it can also be produced by CD4+ T cells NK cells, 
neutrophils and keratinocytes [175, 176]. The gene encoding for TNF-α is located 
on chromosome 6, nearby the Major Histocompatibility Complex (MHC) [177]. 
The TNF-α protein is released upon cleavage of its precursor pro-TNF-α expressed 
on the cell membrane, and it has a tight relationship with matrix metalloproteases 
(MMPs), which inhibition has been show to prevent the pro-TNF-α processing 
[178]. Moreover, evidences of a potential synergism between IFN-g and TNF-α 
in inflammatory atherogenesis have been proven [179], providing a rationale for 
dual cytokine antagonism since psoriasis and atherosclerosis share many similar 
underlying inflammatory mechanisms. 
Collectively, the cytokines IL-17, IFN-γ, IL-22, and TNF can cause keratinocyte 
proliferation as well as production of chemokine, cytokine, and antimicrobial pep-
tides, acting both independently or in exerting a synergistic effect. This becomes 
a self-amplifying loop, where these products act back on the DCs, T cells, and 
neutrophils to perpetuate the cutaneous inflammatory process [148, 164, 180-182].
1.2.4 Treatment of psoriasis
Depending on the severity of the disease, appropriate treatment can be initiated. 
Topical therapies (corticosteroids, vitamin D analogues and calcineurin inhibi-
tors) are used for the treatment of mild-to-moderate psoriasis without PsA, while 
moderate-to-severe psoriasis patients are generally treated with phototherapy, 
methotrexate, retinoids or biologics [88, 183-185]. Phototherapy involves the 
use of UVB or psoralen plus UVA (PUVA) [84], with an efficacy that leads from 
50% to 70% of patients achieving at least 75% PASI improvement after 4-6 weeks 
[186]. The phototherapy mechanisms of action are multiple: promotion of inflam-
matory cells (e.g. APC) apoptosis, stimulation of anti-inflammatory cytokine IL-10 
production, with Th17 cell suppression and Th2 and regulatory T-cells activation 
[187]. Retinoids, analogs of vitamin A with the ability to inhibit epidermal cell 
proliferation and differentiation [188], have been used since the 80’s [189] for the 
treatment of psoriasis vulgaris, alone or combined with UV light treatment [190]. 
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Two of the traditional systemic therapeutics are methotrexate, synthetic analog 
of folic acid which downregulates the psoriatic key inflammatory cytokines and 
chemokines IL-17, IL-22, IL-23 and CCL20 [191], and cyclosporine, which acts 
by inhibiting T cell activity through the inhibition of calcineurin, a phosphatase 
that promotes the expression of the pro-inflammatory cytokine IL-2 [192]. Other 
well-known systemic therapeutics are acitretin, apremilast and fumarates [193-195].
Newest treatment targets discovered with the latest research on the immunopatho-
genesis of psoriasis opened new exciting therapeutic options with biological agents 
(or biologics). Biologics are drugs that selectively target specific molecules and 
are manufactured in living systems such as cells [183, 184, 196, 197]. TNF-α 
blockers, firstly implied in the treatment of rheumatoid arthritis (RA), were rap-
idly expanded to the treatment of psoriasis and psoriatic arthritis too, due to their 
ability to act on the IL-23/IL-17A axis and reduce the inflammatory effects by 
downregulation of IL-17A and/or its signaling pathway [198]. In 2004, the TNF-a 
antagonist etanercept (a recombinant human fusion protein rather than a monoclonal 
antibody) was the first biologic agent approved to treat psoriasis [199, 200]. After 
this, other TNF-α blockers have been released, such as infliximab, adalimumab 
and certolizumab pegol [201-204]. Secukinumab, ixekizumab (approved anti-
IL-17A ligand monoclonal antibodies) and brodalumab (approved anti-IL-17RA 
monoclonal antibody) are biological antagonist of IL-17 pathway [129, 183, 184, 
197]. Ustekinumab, on the other end, it’s a monoclonal antibody directed against 
the subunit-β (p40) shared by both IL-12 and IL-23 cytokines, which inhibits the 
downstream signaling pathways (including IL-17) [205]. 
Newest biologics for the treatment of psoriasis through targeting the p19 subunits 
specific for IL-23 cytokine are guselkumab (FDA approved in 2016), a human 
immunoglobulin G1 lambda (IgG1l) monoclonal antibody able to get efficacy 
91% PASI 75 [206], tildrakizumab which, alike ustekinumab, it requires follow-up 
injection doses every 12 weeks [207], risankizumab [208, 209] and mirikizumab 
[210]. Bimekizumab, the first biologics able to neutralize simultaneously IL-17A 
and IL-17F, has shown extremely promising results already at phase IIb clinical 
trials, being able to reach efficacy 94% PASI 75 at week 12 and 60% PASI 100 
at week 12 [211].
Finally, blocking IFN-g pathway with specific antibodies has shown little or no 
therapeutic effect [212], another reason why, as mentioned earlier, it is believed 
that this cytokine plays a major role in the activation of antigen-presenting cells 
in the initiation phase of psoriasis, rather than maintaining the lesional psoriasis 
phenotype [168].
Nevertheless, due to limitations in the actual therapies, newer treatments (both 
systemic and topical) are still needed. For example, patients treated with IL-17A 
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blockers have increased predisposition to develop Candida albicans infections 
[213] or have inflammation at the gut mucosa, where the cytokine IL-17A has a 
protective role [150]. On the other hand, the selective IL-23p19 inhibitors have 
shown an impressive safety profile with no contraindications nor side effects 
reported within the data collected in the last few years [214]. In an ideal situation, 
the best treatment for psoriasis would be the one which gives a perfect clearance 
of the disease, with 100% PASI improvement in all the treated patients, with no 
side effects, that’s convenient and easily accessible at low cost.
1.2.5 Comorbidities of psoriasis
Psoriasis is equally prevalent in both sexes, although it has been recently shown 
to be present in a more severe form on average in men [215] and it is considered 
an immune-mediated systemic inflammatory disease [216] associated with dif-
ferent comorbidities [217-219]. Among the classic comorbidities, we can find 
psoriatic arthritis (PsA), inflammatory bowel disease (IBD), metabolic syndrome 
(hypertension, obesity, diabetes, hyperlipidemia), cardiovascular diseases (CVD), 
psychological and psychiatric disorders (especially depression) and uveitis [219]. 
Those instead considered as emerging comorbidities in psoriasis are chronic liver 
diseases such as hepatitis and nonalcoholic fatty liver disease (NAFLD), lympho-
mas, chronic obstructive pulmonary disease, sexual dysfunction, obstructive sleep 
apnea (OSA), osteoporosis and even Parkinson’s disease [218-220].
Up to one third (~30%) of patients with psoriasis develop psoriatic arthritis during 
the course of the disease; today, the term “psoriatic disease” is used which includes 
both cutaneous psoriasis and PsA being part of the same disease [221]. PsA is a 
seronegative inflammatory polyarthropathy with an age of onset in between 30 to 
55 years, it affects men and women equally and it involves the peripheral joints 
(arthritis), axial skeleton (spondylitis), insertion of tendons and ligaments into 
bone (enthesitis), inflammation of whole digits (dactylitis) [222]. In the majority 
of cases, PsA appears years after the onset of cutaneous psoriasis –5 to 10 years 
for the manifestations to take place [223]. However, even in patients with known 
psoriasis, PsA is difficult to diagnose and it is common that patients get a diagnosis 
many years after the onset of joint symptoms [224]. The unspecific symptoms make 
the diagnosis challenging, and it is estimated that the prevalence of undetected 
psoriatic arthritis among patients with cutaneous psoriasis is to be between 10% 
and 15% [225]. Moreover, genetic susceptibility regions for psoriasis vulgaris and 
psoriasis arthritis are partially shared but not identical [226].
In recent years, tools to accurately measure the disease activity and questionnaires 
for patient’s self-assessment have been made accessible to clinicians attempt-
ing to perform accurate diagnosis of psoriatic arthritis [227, 228]. The CASPAR 
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(ClASsification for Psoriatic ARthritis) criteria [229] is an accurate classification 
method that collects previously published principles to classify psoriatic arthritis 
and further develop them to improve their sensitivity and specificity for the diag-
nosis of the disease. The DAS28 (28-joint Disease Activity Score) [230], origi-
nally created to assess rheumatoid arthritis progression and improvement upon 
treatments, consists of the measurement of twenty-eight joints including proximal 
interphalangeal joints, metacarpophalangeal joints, wrists, elbows, shoulders and 
knees, taking into account both tender and swollen joints. The BASDAI (Bath 
Ankylosing Spondylitis Disease Activity Index) is a score that quantifies the dis-
ease activity in axial psoriatic arthritis [231]. Despite the positive correlation of 
this with other disease activity scores, it is not able to discriminate patients with 
active peripheral psoriatic arthritis only from those with active axial and peripheral 
musculoskeletal disease. Recently, BASDAI has been implemented by combining 
it with the results from the CRP (C reactive protein) of the patients with cutaneous 
psoriasis, producing a new score system called ASDAS (Ankylosing Spondylitis 
Disease Activity Score) [232].
The currently available clinical markers for psoriatic arthritis such as scalp and 
intergluteal psoriasis, nail changes [233] as well as dactylitis, juxta-articular bone 
formation and negativity for the rheumatoid factor are not enough to obtain an 
accurate prediction of the disease progression (Figure 8). More recently soluble 
biomarkers including pro-inflammatory cytokines such as IL-6, CXCL10, as well 
as MMP3, high-sensitivity CRP and CPII have been proposed as screening mark-
ers for the identification of psoriatic arthritis in patients with cutaneous psoriasis 
[234, 235]. However, at the time of writing, no reliable biomarkers are available 
for this purpose in clinical practice.
Figure 8. Clinical features of psoriatic arthritis (PsA). (a) Involvement of the distal inter-
phalangeal (DIP) joint in psoriatic arthritis. (b, c) Patient with arthritis mutilans displaying 
polyarthritis, evident psoriatic nail changes, and reduction in length of the first digit on the 
right hand. Reproduced and adapted with permission from P.J. Mease and P.S. Helliwell, 
2008, “Atlas of Psoriatic Arthritis”. Copyright© Springer-Verlag London Limited 2008.
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1.2.6 Psoriasis-like animal models
Psoriasis it is a skin disease that primarily affects the human species and, besides 
few primates, no other animals present natural occurrence of skin inflammation or 
phenotype that resemble psoriasis [236]. Aiming to obtain better models to study 
the pathogenesis of the disease and support in vitro cell culture results, an effort 
was made by the research community to develop murine models with characteristics 
as similar as possible to psoriasis in human. The mice models can be represented 
in three major groups: (i) genetically engineered, (ii) humanized xenograft and 
(iii) acute or inducible [237-240].
The first group represents a mouse model with perturbations (transgenic or knock-
out) of specific genes associated to psoriasis, and it can be either whole-body or 
conditional tissue-specific (skin-specific in this case) [239, 241]. Few examples 
are transgenic mice for Vegf [242], Tgf-β [243], Il-36 [244], Stat3 [245], Pparβ/d 
[246], and knockout mice for Cd18 [247], Il-1rn [248], Ikk2 [249], JunB and Jun 
(c-Jun) [250], Ifnr-2 [251] or Il-36RA [252].
The second group consists of immunodeficient mice receiving human lesional or 
non-lesional psoriatic skin xenotransplanted on their back, which can be followed 
by a step of transferring T cells [239, 253, 254]. Boyman et al. in 2004 described 
a new xenotransplantation model, showing spontaneous formation of psoriasis-
like skin lesions when human psoriasis non-lesional skin was transplanted onto 
AGR129 mice [255]. Here healthy skin grafted onto mice as control did not show 
psoriasis-like phenotype. A reason for this could be the increased number of T cells 
in non-lesional compared to healthy skin [256], although it has been proven that 
injecting T cells in healthy skin could not convert it into non-lesional psoriatic skin 
[257]. A possible explanation might be related to the absence of auto-antigens trig-
gering the dendritic cells, which further promote the psoriasis-like phenotype [258].
The third group, in particular the imiquimod-induced model, is one of the most 
used psoriasis-like model to study this disease. Characterized and reported for the 
first time in 2009 [259], this model consists in first shaving the back of the mice 
in order to expose their skin, followed by the topical application of 62.5 mg of 
imiquimod cream (5% IMQ, Aldara, 3M Pharmaceuticals, St Paul, MN) [260]. 
The topical re-application of the synthetic imidazoquinolone amine compound 
occurs daily and lasts for about 5 to 7 days [259]. Use of Aldara cream was initially 
exclusive to treat skin malignancies such as basal cell skin carcinoma (BCC), actin 
skin keratosis and, occasionally, melanoma [261, 262]. Although the mechanism 
of action of imiquimod is not completely understood, it is now well established 
its role as ligand of the toll-like receptors TLR-7 and, to a smaller extent, TLR-8 
[263]. The agonistic activity exerted by imiquimod towards these TLRs promotes 
infiltration of plasmacytoid dendritic cells (pDCs) and activation of IL-23/IL-17 
26
axis, followed by downstream inflammatory signaling events, including the trans-
location to the nucleus of the transcription factor NF-kB. This results in the pro-
duction of the pro-inflammatory cytokines IL‐2, IL‐6, IL‐8, IL‐12, IFNα, TNF-α, 
chemokines CCL2, CCL4, CCL4, as well as NF-kB-independent cytokines such 
as IFN-γ [264]. The application of imiquimod on the skin of mice results in hyper-
plasia of the epidermis with keratinocytes increased proliferation accompanied 
by erythema, scaling, acanthosis and impaired epidermal differentiation [259], all 
characteristic features of human psoriasis which make this model widely accepted 
as model of lesional skin development [239, 265]. From the transcriptomic point 
of view, different strains used to recreate this model have shown differences in 
the gene signature upon imiquimod application, with the C57BL/6 J (B6) being 
the most consistent, best-replicating the gene alterations found in human psoriasis 
lesions [266].
Direct intradermal injection of IL-23 cytokine in mice was also shown to induce 
inflammation and phenotypic effects similar to psoriasis, through the CCL20 
receptor CCR6 [267, 268]. A study showed that ear injection of IL-23 in IL-22−/− 
mice resulted in low ear swelling and epidermal hyperplasia but same results 
were obtained in IL-17−/− normally expressing IL-22, suggesting the importance 
of IL-17A in mediating psoriasis-like inflammation and phenotype in this mouse 
model [135]. On the other hand, mice lacking the CCL2-ligand receptor CCR2 –
important for different immune diseases, including psoriasis– following injection 
with IL-23 had increased production of Th2-depdendent cytokines such as IL-4, 
characteristics of atopic dermatitis-like inflammation [269]. This suggests careful 
consideration when using this model for psoriasis related studies.
1.3 Protein-coding RNAs
The human genome is constituted of ~2-3% of DNA which is transcribed into RNA 
and this, once exported from the nucleus to the cytosol, is translated into proteins 
[270-272]. Protein-coding genes could be in single copy or in tandem clusters –a 
collection of identical copies of genes which are transcribed simultaneously, in 
order to increase the transcription output of these genes [273, 274]. The proteins 
resulting from the transcription of protein-coding genes belong to different catego-
ries, i.e. cytokines, growth factors, receptors, transcription factors, phosphatases, 
structural proteins and transporters (Figure 9). The exact number of these protein-
coding genes is not clearly understood yet (approximately 20-25,000 in the human 
genome) and can be different between individuals, as well as between different 
cell types in the same individual [275, 276]. The gene transcription rate can be 
altered by variations in our DNA, serving as a marker for the onset of complex 
traits or disorders [277, 278]. An example is TP53 (OMIM #191117), probably the 
gene with the highest frequency of mutation in the human genome, that leads to 
the altered expression of its p53 protein. This, in turn, loses its activity as tumor 
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suppressor and gains functions that promote the development of cancer in differ-
ent cells and organs [279-281]. A variety of protein-coding genes are known to 
be altered in the skin, having potential implications in skin aging [282, 283] and 
being directly implicated in the pathogenesis of multiple skin diseases [284, 285].
Figure 9. Human genome classification according to functions of its genes transcribed 
into proteins. Percentage of genes serving for each function it is given.
Some parts of the genome are transcribed into RNA which, on the other hand, is not 
translated into proteins. This give raise to a class of RNA called non-coding RNA.
1.4 Non-coding RNAs
About 97-98% of the approximately 3 billion base pairs that compose the human 
genome was referred to as “junk DNA” [286] and simply considered useless 
for decades. Our understanding of the genome has advanced tremendously with 
improved genomic technologies that have enabled scientists to finally bring the 
picture into focus. An important role in the RNA revolution occurred in this field 
was played by the ENCODE [287, 288] and FANTOM projects [289, 290]. Thanks 
to these consortiums, it was clear that a large part of the non-protein-coding genome 
is indeed transcribed into RNA [291]. Since the discovery of the small regulatory 
RNA which does not code for proteins called microRNAs (such as lin-4 and let-7) 
in the 1990s, our understanding of ncRNAs as regulatory molecules continuously 
evolved [292-294]. Following studies shed some light on new categories of non-
coding RNAs, such as small nucleolar RNA (snoRNAs), responsible for chemical 
modifications of rRNAs (most abundant RNA molecules in the cell) and tRNAs 
(decode the mRNA sequence into peptide or protein), and PIWI-interacting RNAs 
(piRNAs), which preserve the genomic integrity by suppressing mobile genetic 
elements [295-297]. Moreover, more than 10,000 RNA molecules longer than 
200 nucleotides, called long non-coding RNAs (lncRNAs) have been reported in 
human [298-300]. Still largely uncharacterized category, recent works suggested 
multiple roles of the lncRNAs, such as the epigenetic control of gene expression, 
promoter-specific gene regulation, X-chromosome inactivation, imprinting, main-
tenance of nuclear architecture, often in accordance to their cellular localization 
(nuclear or cytoplasmic) [301-304]. A simplified classification of the coding and 
non-coding RNA classes is shown in Figure 10.
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Figure 10. Major classes of coding and non-coding RNAs in the eukaryotes.
1.4.1 MicroRNAs
Among the non-coding RNAs, microRNAs (miRNAs) are the most well char-
acterized and most conserved among species. miRNAs are short RNAs (~19-25 
nucleotides) which previously were not considered to have any function [305]. The 
interest for microRNAs began with the discovery of lin-4, a small RNA molecule 
of 22 nucleotides which interferes with a specific developmental transition phase in 
Caenorhabditis elegans [292]. For almost seven years no studies were published in 
the field, until a second similar short RNA, called let-7 (lethal-7), was discovered 
[294]. The peculiarity of let-7 is that it is one of the most conserved elements in the 
animal kingdom (100% conserved sequence between flies and humans), suggesting 
a role of this small molecule family in the genome. MicroRNAs have extremely 
high tissue-, cell- and sometimes species-specificity compared to protein-coding 
genes [306]. Today, microRNAs are considered to be fundamental regulators of 
gene expression, in addition to epigenetic, transcriptional, translational regulation 
and other kind of modifications [292]. In human more than 2,000 miRNA genes 
are known (even more than any other transcription factor family). 
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1.4.1.1 MicroRNA biogenesis and functions
MicroRNAs, alike protein-coding genes, are encoded in the DNA and transcribed 
by RNA polymerase II into a long primary transcript (pri-miRNA) [307]. This 
forms hairpins which is cleaved-off by a microprocessor complex composed of 
Drosha (RNase III endonuclease) [308] with its cofactor DGCR8 and exported to 
the cytoplasm in the form of precursor microRNA (pre-miRNA; 60-70 nucleo-
tides) by the carrier exportin 5 (XPO5) [309]. Here the terminal ends are further 
cleaved by the RNAse III enzyme DICER (with TRBP or PACT) [310], processing 
the pre-miRNA into a double-stranded RNA (~22 nucleotides); one strand of the 
resulting microRNA-duplex is incorporated into a larger protein-complex called 
RISC (RNA Induced Silencing Complex), which includes the argonaut protein 
2 (AGO2) [310, 311]. This complex mediates the binding of the mature miRNA 
seed sequence to the 3’ untranslated region (UTR) of the target messenger RNA(s) 
[292]. Therefore, if a microRNA is expressed in the cell, the protein synthesis will 
be inhibited since the ribosome cannot translate the RNA when RISC is bound to 
it [312, 313]; alternatively miRNA-induced mRNA degradation can occur [314, 
315]. MicroRNA biogenesis is summarized in Figure 11.
Since the mRNA interaction with the seed sequence of the miRNA is short (6 to 
8 nucleotides), hundreds or even thousands of genes can be targeted by the same 
miRNA, which can in this way simultaneously regulate different biological pro-
cesses and pathways [316].
Very often miRNAs have relatively mild effect on selective mRNAs, but the tar-
get itself is not randomly chosen from the transcriptome; indeed, a miRNA may 
regulate a receptor, some components of the signal transduction pathway and 
transcription factors, inducing rather dramatic phenotypes [317, 318].
Some microRNAs reside in introns of both protein-coding genes and long non-
coding RNAs, while few exceptions reside in the exons [319-321]. Another inter-
esting feature of the miRNAs is their coexistence in more copies in the genome; 
they can be present on different chromosomes and in multiple copies, confirming 
their robust transcription (they are abundantly present) [322].
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Figure 11. Model of microRNA biogenesis and posttranscriptional regulation of genes. 
Reproduced and adapted with permission from Mulrane L et al., 2013; Cancer Research. 
Copyrights© 2013 AACR
1.4.1.2 MicroRNAs in skin and psoriasis
The potential of microRNAs in the global regulation of gene expression and devel-
opmental transitions during mammalian skin development, led to an increased 
interest in the function of these messenger-RNA regulators in stem cell biology 
and developmental biology [323]. Some of the most abundant microRNAs such 
as miRNA-200 and miRNA-19/miRNA-20 families, have epidermis-specific 
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 expression while the miRNA-199 family is largely expressed in the hair follicles 
[324]. In 2007, our research group showed for the first time altered expression 
of a set of miRNAs in psoriasis skin, with a microRNA signature distinct from 
healthy skin and also from atopic dermatitis, another inflammatory skin disease. 
Further studies from our group have demonstrated that differentially expressed 
miRNAs regulate cellular processes with relevance for psoriasis, such as keratino-
cytes proliferation and differentiation (miR-125b, miR-203) [325], apoptosis of 
activated T cells (miR-21) [326], keratinocyte-immune cell cross talk (miR-31) 
[327] and regulation of IL-17- and Toll-like-receptor (TLR)-mediated inflamma-
tory responses in keratinocytes [328, 329]. Other groups have identified additional 
miRNAs in the context of psoriasis such as miR-135b, which regulates keratinocyte 
differentiation and proliferation [330, 331], miR-136 that provide regulation of 
TGF-β1-induced keratinocyte proliferation arrest [332, 333]. Zibert et al. miRNA 
profiling studies in psoriasis identified miR-21, -205, -221 and -222 targeting 
mRNAs having a role in cellular growth, epidermal development, proliferation, 
apoptosis, degradation of the extracellular matrix and immune and inflammatory 
responses [333]. In addition, combining NGS and LCM, Løvendorf et al. identified 
miR-193b down-regulation and miR-223 up-regulation in Th17 cells of dermal 
infiltrates of psoriatic plaques [334].
MicroRNAs have a therapeutic potential in patients with psoriasis. For example, 
the role of miR-146a in psoriatic patients was assessed by our group, using miR-
146a–/– mice in conjunction with the imiquimod-induced mouse model of psoriasis 
[329], and by others [335, 336], as well as by Rebane et al. in atopic dermatitis 
[337]. miR-21 inhibitor study on the xenograft model have proven impaired tran-
scriptional activity of Jun/activating protein 1 (AP-1), followed by activation of 
IL-6 and Stat3 signaling pathways in psoriatic lesion [338].
1.4.1.3 Circulating microRNAs as potential biomarkers
While miRNAs act within the cell, they are also present in cell-free body fluids 
such as blood, serum, plasma, saliva etc., partially within extracellular vesicles 
(EVs), partially bound to lipids or proteins (LTPs, lipid-transfer proteins) repre-
senting non-vesicular carriers [339, 340]. MiRNAs circulating within extracellular 
vesicles in body fluids are very stable since resistant to degradation by RNases. 
This makes them ideal candidates as biomarkers [341, 342]. Beside their hypoth-
esized role as mediator of intracellular communications [343], circulating miRNAs 
have also been proposed as biomarkers in several diseases, in particular cancer 
but also in inflammatory and metabolic diseases [344-348], as well as ageing and 
age-associated disorders [349]. More recently, circulating microRNAs have found 
interest as potential biomarkers in skin-related diseases such as melanoma, for 
either diagnosis, recurrence and/or progression [350, 351]. Very little is known 
about microRNAs as biomarkers in psoriasis but detection of some of them (such 
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as miR-223 and miR-143) has been proven to provide potential clinical applica-
tions for diagnosis, prognosis, and treatment responses of psoriasis [352, 353]. 
Increased serum levels of miR-33 and miR-424 have been found in psoriasis 
patients compared to healthy controls [354, 355]. A recent study proposed six 
miRNAs (miR-221-3p, miR-130a-3p, miR-146a-5p, miR-151-5p, miR-26a-5p and 
miR-21-5p) with significant up-regulation in serum of psoriatic arthritis patients 
compared to healthy controls, as potential biomarkers for PsA [356]. Finally, in 
2013 our group observed four circulating miRNAs whose levels were significantly 
altered (increased: miR-128a; decreased: let-7d, miR-142-3p, miR-181a) in pso-
riasis compared to healthy serum, as well as upon anti-TNF-α treatment [357].
Figure 12. Circulating microRNAs enclosed in different compartments including vesi-
cles (exosomes, microvescicles, multi-vesicular and apoptotic bodies), protein and lipid 
complexes. Reproduced and adapted with permission from Kumarswamy R et al., 2013; 
Circulation Research. Copyrights© American Heart Association.
1.4.2 Long non-coding RNAs
LncRNAs are transcripts longer than 200 nucleotides in length, they are mostly 
(but not all) transcribed by the RNA polymerase II, 5’-capped, spliced, some-
times polyadenylated and they appear not to have conserved open reading frames 
(ORFs), thus without protein production capacity, but still sharing traits with 
their protein-coding mRNA cousins, such as exhibiting intron-exon splicing and 
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regulated transcriptional control [358, 359]. In 2001, Mattick et al. proposed long 
non-coding RNAs and introns as part of a unique network with properties like 
supporting communications between genes, hypothesizing a superior complexity 
of the eukaryotic genome in carrying out multiple tasks simultaneously [360, 361]. 
In 2005, the FANTOM3 project started shading some light on the transcriptional 
complexity of mammalian genomes. Thanks to the so-called CAGE (Cap Analysis 
Gene Expression) and GIS (Gene Identification Signature), it was possible to 
precisely map the 5′ and 3′ ends of transcripts from 237 full length cDNA librar-
ies prepared from a wide collection of mouse cells and tissues [358]. According 
to the ENCODE project [287, 288], between 10,000 and 200,000 lncRNAs are 
estimated to be present in the mammalian genome [362, 363]. Some of the most 
well-known lncRNAs are Xist (X-inactive specific transcript), discovered in 1991, 
with a role in the chromosome X inactivation [301] and H19, the very first lncRNA 
discovered in Eukaryotes, with multitasking properties [364].
Transposable elements (TEs), which represent about 40-45% of the genome [272], 
are considered the main contributors of long non-coding RNAs origins and diver-
gences among different species [365-367] (Figure 13). Although a broad spectrum 
of lncRNAs are also known to originate from pseudogenes [368-370].
Since lncRNAs often have little homology across species, model systems where 
to study them must be chosen carefully. They are typically expressed at much 
lower levels than mRNAs and very sensitive detection methods are required to 
measure changes in expression [371, 372]. They can exist in complex genome 
sites between protein coding genes, within genes or even overlapping other genes, 
making crucial the specificity of the assay used for detection. Despite being a 
relatively new field, lncRNAs are gaining enormous interest from researchers, 
principally because they can play significant roles in our biology such as (1) cell 
development and differentiation [373], (2) epigenetic regulation [363] and (3) 
pathogenic disease [374], all processes where they might represent a new class of 
biomarkers or druggable targets for cancer, heart disease, inflammation, diabetes 
and neurodegeneration just to name a few.
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Figure 13. LncRNA expression divergence between species. Content of protein-coding 
(red) and long non-coding RNAs (blue) in different species during evolution. Ttransposable 
elements (TEs) and size of the genome are shown in gray. Reproduced and adapted with 
permission from Kapusta A & Feschotte C, 2014; Trends in Genetics. Copyrights© 2014 
Elsevier Ltd.
1.4.2.1 Genomic location of lncRNAs
According to where they are found relative to nearby protein-coding genes, long 
non-coding RNAs are transcribed from intergenic regions, exons, introns, and 
overlapping regions [372]. Intronic lncRNAs are actively transcribed and spliced 
from the intron of a protein-coding gene, while long intergenic non-coding RNAs 
(lincRNAs) are transcribed from intergenic regions [375, 376]. Antisense lncRNA 
are generally transcribed from the antisense strand of genes coding for proteins 
[377] , while sense lncRNA are transcribed from the sense strand and can overlap 
with part of protein-coding genes or covering the entire sequence of a protein-
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coding gene through an intron [378]. Conservation among species has been shown 
to have direct association with the genomic location of lncRNAs [379]. 
1.4.2.2 Mechanisms of action of lncRNAs
The features of the lncRNAs allow them to direct epigenetic complexes in cis (on 
the chromosome from which they are transcribed) or in trans (other chromosomes 
from which their transcription occurred) [380]. They are unique in their ability 
to act in an allele-specific way, as they are tethered to the locus in cis during the 
transcription. Because the RNA molecule is functional and its structure will often 
dictate function, the secondary and tertiary structures of lncRNAs help to deter-
mine their role(s) [381, 382]. Long non-coding RNAs can function in multiple 
ways, according to their nuclear or cytoplasmic localization and whether they are 
in cis- or in trans-acting lncRNAs [383].
Enhancers: linking three-dimensional chromosome conformations by taking 
enhancers to their target promoters or activator sites along the genome, mediat-
ing the activation of neighboring genes or transcripts. The expression of these 
enhancer RNAs (eRNAs) usually correlates with the expression of neighboring 
genes [384, 385].
Guides (e.g. XIST in cis and HOTAIR in trans): the lncRNA can bind the epige-
netic complex in a sequence-specific manner, “guiding” the epigenetic machinery 
in its processes, for example histone methylation [301, 303, 386].
Scaffolds (e.g. HOTAIR and NEAT1): they mediate the formation of large ribo-
nucleoprotein complexes, binding other RNAs through base pairing and so act-
ing as sensors for mRNAs, miRNAs or other lncRNAs; they can also bind one or 
more proteins through separate domains. Essentially when the lncRNA acts as a 
scaffold, rather than just recruiting one complex it tends to recruit more, bringing 
them somewhere else [386].
Decoys (e.g. MALAT1): provide binding sites for DNA binding proteins or other 
regulatory molecules, preventing them from binding their targets. For example, 
they can act as a “sponge” on specific microRNAs, moving them away and deter-
mining their gene regulation [386, 387].
Signals: where basically is the transcription itself running through a locus which 
has the function, rather than from the lncRNA that’s being produced [387]. 
Reservoirs: such as H19 which acts as reservoirs for specific miRNAs in order to 
release them in a secondary moment [388].
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Other lncRNAs features are represented by the formation of RNA-protein com-
plexes which influence the regulation of gene expression [389], and their interac-
tion with DNA [390] and other RNAs [391] through their secondary structures. 
Moreover, studies have shown that long non-coding RNAs can have a role in dosage 
compensation [392], genomic imprinting [393] and they can act as transcriptional 
activators [394] or repressors [395].
This section has the aim to give more insights to the long non-coding RNAs 
mechanisms of action previously described, according to their subcellular locali-
zation (Figure 14).
Generally, nuclear lncRNAs are involved in gene regulatory processes [396], 
including transcriptional regulation through the interaction with the transcription 
preinitiation complex at the promoter-specific level –in turn, this alters the local 
chromatin accessibility. The lncRNAs Evf-2, also known as DLX6-AS1 and LED 
(LncRNA activator of Enhancer Domains), appears to act as a transcriptional activ-
ity modulator at enhancers sites [397]. In the cell nucleus they can also simultane-
ously activate/repress multiple gene loci through the modulation of the chromatin 
accessibility, promoting epigenetic gene regulation (examples are the lncRNAs 
FENDRR and HOTAIR) [363, 398, 399]. Finally, several nuclear lncRNAs might 
be capable to regulate the nuclear architecture. Examples of this type of regula-
tion are the X chromosome inactivators FIRRE and XIST [400, 401] and NEAT1, 
a lncRNA associated to paraspeckles in the nucleus [402, 403]. Upon specific 
inflammatory signals, it can dissociate from the paraspeckles, translocate to the 
cytoplasm and regulate the expression of genes involved in the activation of the 
inflammasome in macrophages [404] or in different cancers [405, 406].
Long non-coding RNAs residing in the cytoplasmic compartment have been 
shown to be involved in the control of mRNA stability through targeting double 
stranded binding regions of the mRNA target, providing positive and negative post-
transcriptional gene modulation [407]. An example is the cytoplasmic lncRNA 
TINCR (terminal differentiation-induced ncRNA) shown by Kretz et al., which 
directly interacts with ds-binding protein Staufen-1 (STAU1), promoting mRNA 
degradation [408]. This reflects the role of certain lncRNAs as regulators of the 
translation. For example, lncRNA-p21 can directly modulate the translation of 
messenger RNAs such as JUNB and CTNNB1 through the RNA-binding protein 
HuR; if HuR is not available, lncRNA-p21 can repress the translation of these 
mRNAs [409]. At last, cytoplasmic lncRNAs can also regulate gene expression 
by acting as microRNA sponges, also known as competing endogenous RNAs 
(ceRNAs) [410]. This is because the lncRNA-miRNA complex does not allow the 
microRNA to reach the actual target, modulating miRNA-mediated silencing of 
the messenger RNA [411, 412]. Other examples of miRNA sponges are the cir-
cularRNAs (circRNAs) [413], such as circNRP1, which promotes gastric cancer 
progression by sponging the miRNA miR-149-5p [414].
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Figure 14. Functions of nuclear and cytoplasmic long non-coding RNAs. Nuclear localized 
lncRNAs can act as 1. Transcriptional repressor by interacting with both DNA element 
and transcription machinery 2. Enhancer by docking transcription factors to regulate gene 
expression in cis and trans. 3. Epigenetic regulators by guiding chromatin modifiers to 
different genomic location 4. Regulator of nuclear architecture by mediating inter chromo-
somal interaction. Cytoplasmic lncRNAs function as 5. MiRNA sponges to hijack several 
miRNAs at a time. 6 and 7. Regulator of mRNA stability by interacting with different mRNA 
binding proteins 8. Translational activator by recruiting ribosomes to 5’cap. Reproduced 
and adapted with permission from Hombach S and Kretz M, 2016; “Non-coding RNAs: 
Classification, Biology and Functioning”. Copyrights© Springer International Publishing 
Switzerland 2016.
1.4.2.3 Long non-coding RNAs in skin and psoriasis
Several lncRNAs appear to be expressed only in specific conditions, such as 
precise developmental time points [415, 416] or in response to stress and other 
external signals [417]. To date, little is known about the role of lncRNAs in normal 
skin biology and in psoriasis. The first lncRNA described in psoriasis was PRINS 
(Psoriasis Susceptibility-Related RNA Gene Induced by Stress), a lncRNA showing 
up-regulated expression already in non-lesional psoriatic epidermis, which regu-
lates the stress response of keratinocytes and it has equal expression throughout all 
the epidermal layers [418] (Figure 15). Studies by Kretz et al. have characterized 
the role of two lncRNAs in epidermal differentiation. TINCR (terminal differen-
tiation-induced ncRNA) [419], which is mostly expressed in the differentiation 
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 compartment (suprabasal layer of the epidermis) and ANCR (anti-differentiation 
ncRNA) [420], more abundant in the basal layer of the epidermis, where progeni-
tor cells reside (Figure 15). A recent study from Gupta et al. characterize the long 
noncoding RNA transcriptome in lesional full-depth skin from psoriasis patients 
before and after treatment with adalimumab monoclonal antibody. RNA-Seq analy-
sis revealed that almost one thousand lncRNAs were significantly deregulated in 
the psoriasis lesion after the treatment with adalimumab [421]. Similarly, weighted 
gene co-expression network analysis (WGCNA) on RNA-seq data from psoria-
sis patients (before and after treatment with adalimumab) and healthy controls, 
allowed the detection of specific networks and pathways previously not identified 
through differential expression analysis, with potential roles for lncRNAs [422]. 
The RNA-Seq study from Tsoi et al. aimed to identify deregulated lncRNAs in 
psoriasis patients, including full-depth skin biopsies from lesional and non-lesional/
uninvolved psoriasis, as well as from healthy donors [423]. Their computational 
approach resulted in the detection of about three thousand lncRNAs with known 
annotation and about thousand novel deregulated lnRNAs with skin-specificity, 
enrichment in the EDC (epidermal differentiation complex) and potential func-
tions in the immunopathogenesis of psoriasis [423].
Figure 15. Long non-coding RNAs PRINS, TINCR and ANCR identified as potential 
regulators of the epidermal homeostasis. Reproduced and adapted with permission from 
Hombach S and Kretz M, 2013; BioEssay. Copyrights© 1999-2020 John Wiley & Sons.
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1.5 Transcriptomic profiling technologies
The DNA, with its nearly 3 billion base pairs, in absence of specific alterations (e.g. 
sun-damage induced mutations) remains unchanged in each cell of an organism. 
What changes is how each part of the DNA (genes) that encodes a specific function 
is expressed and, therefore, how the cell alternates the expression of its genome 
to make proteins, the effectors that allow the modifications. We can then refer to 
“gene expression” talking about a whole series of events that allow certain portions 
of the DNA to be read out and to contribute to a certain function in the cell [424].
We call the mechanism of measuring the levels of each gene in the genome at a 
precise moment “gene expression profiling”. This allows a deeper understand-
ing of the cell’s functions at a certain time [425, 426]. In recent years, several 
techniques have been developed to perform accurate analysis of gene expression 
and identify differences between cell types, their stage of development or their 
function in presence of a pathological condition, as well as producing diagnostic 
tools for specific diseases. 
1.5.1 Microarray
A microarray (or DNA chip) is an array of oligonucleotide probes closely arranged 
on a small solid surface [427]. The probes, which represents oligonucleotide 
sequences of known genes, are synthesized on the solid surface in a way that both 
position and the nucleotide sequence (between 15 to 25 nucleotides in length) are 
known. They can be used to identify genes by hybridization of the DNA from the 
organism to the oligonucleotide probes in the microarray. The DNA of the organ-
ism being studied is fragmented and tagged with a fluorescent dye; the fragments 
are then incubated with the chip and the DNA which is complementary to the 
probes in the microarray bind together, while the unbound DNA is washed away. 
The surface of the microarray is then scanned with a laser beam and the data 
obtained is used to produce a visible image. The intensity of fluorescence is used 
to indicate the extent of hybridization of cDNA (obtained from mRNA) to differ-
ent probes. Over 200 thousand probes can be constructed on a single microarray, 
giving the possibility to quantify an arbitrarily large number of different nucleic 
acid sequences in solution [427, 428].
Being economically advantageous, microarrays are suitable for processing large 
number of samples or for having microarray-based diagnostic tests with clinical 
utility. Moreover, microarray data storage and analysis is less challenging compared 
to the latest technologies. Despite background hybridization is a limitation in terms 
of accurate expression measurements of transcripts low in abundance, microarray 
are still adequate tools to answer specific questions through the investigation of 
well annotated genes, for which probes are designed [429]. In addition, a recent 
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study comparing Affymetrix HTA 2.0 microarray with Illumina 2000 RNA-seq 
for analysis of patient samples identified highly consistent results of gene expres-
sion analysis between the platforms, but discordant results in terms of alternative 
splicing identification, with higher stochastic variability for the RNA-seq data, 
lacking reads for short and low abundant genes [430].
1.5.2 Next-generation sequencing
Genome-wide coverage of transcripts is possible with RNA-sequencing. RNA-
seq is a high-throughput profiling technology at single base resolution with low 
background noise, which can be used to simultaneously map transcribed regions 
of gene expression as well as distinguishing different isoforms and allelic expres-
sion. Compared to microarray, Next-generation sequencing technology does not 
require probes which are species- or transcript-specific (no prior knowledge of 
genome sequence) and has minimal or absent background signal. This allows the 
detection of novel, unannotated transcripts (with deep coverage and high resolu-
tion), novel isoforms from alternative splicing events, fusion genes and single 
nucleotide variants [431-434].
Briefly, the workflow consists first in converting long RNAs into a cDNA frag-
ments library through nucleic acid fragmentations. This is required since the current 
sequencing machines can handle 200-300 bp long fragments. Sequencing adaptors 
are then attached to each cDNA fragment, allowing (i) the sequencing machine 
to recognize the fragments and (ii) to sequence different samples simultaneously. 
PCR will amplify only those fragments with sequencing adaptors. Following 
quality control, which includes verification of library concentration and frag-
ments length, sequencing data is generated at high throughput manner from both 
ends. The resulting sequence reads are then aligned with the reference genome or 
transcriptome and are classified into three types: exotic reads, junction reads and 
poly(A) reads. Expression profile can be generated by using these three types of 
reads and the number of reads that align to each full-length transcript represents 
the expression level of each gene [435, 436]. 
However, RNA-seq has faced some challenges too, such as short reads and PCR-
bias during amplification of the adapter-ligated library. Since the introduction 
of this technology, the system has been updated with increased reads length and 
strand-specificity, which can be used for high levels of mappability and de novo 
assembly of transcriptomes. Moreover, a third generation of NGS abolishes the need 
of genome fragmentation, enabling full-length transcript sequencing and directly 
detecting epigenetic modifications on native DNA [437, 438]. Another concern 
is related to the impact of PCR amplification on the accuracy of gene expression 
quantitation by RNA-seq; this seems to be solved by the new  technologies  including 
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PCR-free library preparation methods for sequencing, such as the Illumina TruSeq® 
DNA PCR-free [439].
With the advent of the RNA-sequencing technology, new implementation com-
bining molecular biology and biochemistry emerged [440]. A summary of some 
of the currently most used sequencing applications to study the transcriptome can 
be found in Table 2.
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Table 2. Summary of the RNA-sequencing applications for transcriptome study.
Methods Description Usage
mRNASeq messengerRNA Sequencing To identify messenger RNAs (mRNAs)
miRNASeq microRNA Sequencing To identify micro RNAs (miRNAs)
GROSeq                         Global Run On Sequencing
To identify nascent RNAs that are 
actively transcribed by RNA Pol IIPROSeq Precision nuclear run-on sequencing
ChIRPSeq Chromatin Isolation by RNA Purification
To discover regions of the genome 
bound by a specific RNA
RiboSeq Ribosome profile Sequencing
To identify RNAs that are being pro-
cessed by the ribosome and hence 
this method helps to monitor the trans-
lation process
CLIPSeq Cross-Linking and Immunoprecipitation Sequencing
To identify the binding sites of cellular 
RNA-binding proteins (RBPs) using 
UV light to cross-link RNA to RBPs 
without the incorporation of photoacti-
vatable groups into RNA
PAR-CLIP Seq
Photoactivatable-Ribonucleoside-
Enhanced Cross-Linking and 
Immunoprecipitation Sequencing
To identify and sequence the binding 
sites of cellular RNA-binding proteins 
(RBPs) and microRNA-containing ribo-
nucleoprotein complexes (miRNPs)
NETSeq Native Elongation Transcript Sequencing
It sequences and captures nascent 
RNA transcripts after immunoprecipita-
tion of RNA Pol II elongation complex
TRAPSeq Targeted Purification of Polysomal mRNA Sequencing
To detect and identify translating 
mRNAs
PARESeq              Parallel Analysis of RNA Ends Sequencing To detect and identify miRNA cleavage 
sites and uncapped transcripts that 
undergo degradationGMUCT Genome-wide Mapping of Uncapped Transcripts
TIFSeq                    Transcript Isoform Sequencing
RNA isoforms are identified after 5’ 
and 3’ paired-end sequencingPEAT Paired-End Analysis of Transcription start site
CELSeq         Cell Expression by Linear amplifi-cation and Sequencing
Single-cell transcriptomics methodsSMARTSeq
Switching Mechanism At the 
5’ end of the RNA Template 
Sequencing
STRT Single-cell Tagged Reverse Transcription
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2 AIMS
This thesis aims to characterize global changes in coding and non-coding gene 
expression of keratinocytes in psoriasis skin, as well as to investigate potential 
circulating biomarkers for the diagnosis of psoriatic arthritis in patients with 
cutaneous psoriasis.
The objectives of the doctoral studies were:
•  To dissect the keratinocyte-specific protein-coding transcriptome of 
psoriasis skin (Paper I)
•  To identify the long non-coding RNA landscape of psoriasis keratino-
cytes and uncover their contribution to the epidermal alterations in the 
disease (Paper II)
•  To explore whether plasma-derived extracellular vesicles microRNAs 
may serve as biomarkers for psoriatic arthritis in patients with psoriasis 
(Paper III)
•  To characterize the role of miR-378a in keratinocytes in psoriasis (Paper 
IV)
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3 MATERIALS AND METHODS
Table 3. Summary of projects’ related material and methods.
Method Sample material Study
Ethics statement Human skin and blood, mice skin I, II, III, IV
Patients, biopsies and study design Human skin and blood I, II, III, IV
Isolation of CD45-negative epidermal cells 
and extracellular vesicles
Human skin and blood I, II, III, IV
RNA extraction Human skin and blood, mice 
skin, cultured cells
I, II, III, IV
Microarray gene expression analysis Human skin, cultured cells I, II, IV
Next-generation sequencing Human skin and blood III, IV
Gene ontology and gene set enrichment 
analyses
Human skin, cultured cells I, IV
Mapping genes in proximity of psoriasis-
associated SNPs
Human skin I, II
Analysis of transcription factor binding site 
motifs
Human skin I
Cell culture, treatments and transfections Human skin, cultured cells I, II, IV
Quantitative real-time PCR Human skin and blood, cultured 
cells
I, II, III, IV
RNAscope in situ hybridization assay Human skin II
Western blotting Cultured cells IV
Mice and the IMQ (imiquimod)-induced 
mouse model of psoriasis
Mice skin IV
Histology and immunohistochemistry Human skin, mice skin IV
Statistical analysis All types of samples I, II, III, IV
3.1 Ethics statement
All the studies which includes human sample material (skin biopsies or blood) 
(study I, II, II, IV) were approved by the Stockholm Regional Ethics Committee 
and conducted according to the Declaration of Helsinki Principles. Written informed 
consent was obtained from all participants (patients and/or healthy donors) prior 
to enrolment. All animal experiments (study IV) were performed only upon 
approval by local ethics committee of Stockholm, Sweden (Swedish Board of 
Agriculture) and in the respect of the welfare of the animals. The ethical permits 
identified by the codes 2007/20-31/2, 01‐258 and N153/14, were in favor of the 
studies included in this thesis.
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3.2 Patients, biopsies and study design
For study I, II and IV, four mm full-depth punch biopsies were taken from the skin 
of healthy volunteers and from age-matching patients with chronic plaque psoriasis, 
from their lesional plaques and healthy-looking non-lesional skin. Biopsies were 
taken at the Department of Dermatology, Karolinska University Hospital (Stockholm, 
Sweden) and at the Swedish Psoriasis Association (Psoriasisföreningen). Biopsies 
from non-lesional/non-irritated skin were taken at least 10 cm from any psoriasis 
lesion. The patients had moderate to severe chronic form of psoriasis and were sub-
ject to examination by expert dermatologists which determined their PASI (Psoriasis 
Area and Severity Index) score at the time of sample collection. Psoriasis patients 
had not received systemic immunosuppressive treatment or UV-B/PUVA treatment 
for at least 4 weeks and topical therapy for at least 2 weeks before skin biopsy. All 
the subjects included in the study were of Caucasian origin. For study III, patients 
in the Stockholm Psoriasis Cohort (SPC) [441] with cutaneous-psoriasis developed 
within one year were enrolled and 500 µL of plasma samples were collected from 
them. Plasma was also collected from the same patients after ten-years of continu-
ous duration of the disease. These patients were closely monitored and a clinical 
examination by expert dermatologists determined whether they developed psoriatic 
arthritis symptoms at the ten-years follow-up visit. Psoriasis Area and Severity 
Index (PASI) was used to quantify the severity of the skin disease and each of these 
patients were assessed for potential psoriatic arthritis symptoms. Rheumatologists 
further examined the patients with subjective joint problems and, if fulfilling all 
the CASPAR (Classification Criteria for Psoriatic Arthritis) [229] criteria, they 
were included in the study as “PsA” (psoriatic arthritis) group. This only in case 
the joint symptoms were not the result of other apparent causes. Patients who 
received rheumatologic examination are in line with the Swedish Early Psoriatic 
Arthritis Registry [442]. Due to the lack of radiographs, evidence of juxta-articular 
new-bone formation was excluded from the assessment of CASPAR in this study. 
Disease activity for patients in the psoriatic arthritis (PsA) group was measured by 
the Disease Activity Score 28 (DAS28), and Bath Ankylosing Spondylitis Disease 
Activity Index (BASDAI). Patients included in the cutaneous-only psoriasis (PsC) 
group had no signs of subjective joint symptoms and no prior psoriatic arthritis 
diagnosis, or this was conclusively ruled out by the rheumatologist. None of the 
patients received any systemic biological or conventional treatment for at least 
four weeks prior the samples collection.
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3.3 Isolation of CD45-negative epidermal cells and 
extracellular vesicles
For study I, II, IV, skin biopsies from psoriasis lesion and non-lesional skin, as 
well as from healthy volunteers, were incubated in dispase (5U/ml) (Thermo Fisher 
Scientific) overnight (about 14-16 hours) at the temperature of 4 °C. Following, 
manual separation of epidermis and dermis was possible using sterile forceps. 
Smaller pieces of epidermis were digested with trypsin/EDTA (Thermo Fisher 
Scientific) to obtain a single-cell suspension. This was purified by depleting 
CD45-positive cells through incubation with CD45-labeled microbeads (Miltenyi 
Biotec) for 15 min at 4 °C and using MACS MS magnetic columns according 
to the manufacturer’s instructions (Miltenyi Biotec). CD45-positive cells were 
retained in the column, while CD45-negative cells (predominantly keratinocytes) 
could easily pass and get harvested. 
For study III, the process of extracellular vesicles (EVs) isolation from patients 
with cutaneous-only psoriasis (PsC) and with established psoriatic arthritis (PsA) 
was performed at Qiagen Genomic Services, Germany, according to their standard 
protocols. Extracellular vesicles were precipitated using miRCURYTM Exosome 
Isolation Kit – Cells, Urine and CSF (Exiqon A/S, Qiagen brand). Before proceed-
ing to RNA isolation, the presence of EVs pellet was determined by the operators 
through visual examination of each sample.
3.4 RNA extraction
For study I, II and IV, total RNA extraction from the sorted CD45-negative cells 
from psoriasis patients and healthy donors was performed using the miRNeasy 
Mini Kit (Qiagen). Briefly, QIAzol Lysis Reagent was added to the samples fol-
lowed by vigorous shake. Upon chloroform addition, the samples were centrifuged 
for 15 min at 12,000 g, 4 °C. Upper phase was collected and the samples were 
alternatively centrifuged and washed with specific buffers. The RNA pellet was 
resuspended in RNase-free water.  Nanodrop spectrophotometer (Thermo Fisher 
Scientific) was used to determine the concentration of the extracted RNA, Agilent 
2100 Bioanalyzer chip (Agilent) was used to assess RNA quantity and RIN (RNA 
integrity number). RNA samples with a RIN >= 9.0 were used for microarray 
analysis (study I, II, IV), microRNA sequencing (study IV) and further quantitative 
real-time reverse transcriptase-PCR. Extraction of total RNA from cultured cells 
is generally performed using TRIzol (Thermo Fisher Scientific) and chloroform 
(Merck KGaA) according to the phenol-chloroform manual nucleic acids separa-
tion method. For study III, RNA extraction was performed at Qiagen Genomic 
Services, Germany, using their standard protocols. Total RNA was extracted from 
extracellular vesicles (EVs) using the miRCURYTM RNA isolation kit – Cell and 
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Plants (Exiqon A/S, Qiagen brand), and RNA spike-in mix (UniSp2, UniSp4 and 
UniSp5, Exiqon A/S, Qiagen brand) were incorporated in the purification step in 
order to keep track of the efficiency of the RNA extraction.
3.5 Microarray gene expression analysis
For study I, for microarray gene expression profiling, 100 ng of total RNA extracted 
from CD45-negative cells was hybridized to the Affymetrix GeneChip® HTA (Human 
Transcriptome Array) 2.0 (Affymetrix; Thermo Fisher Scientific brand). R and the 
Bioconductor package LIMMA (Linear Models for Microarray Data) [443] were used 
for preprocessing of the data, identification of differentially expressed protein-coding 
genes and related statistical analysis. Significantly deregulated genes were selected 
using threshold for linear fold-change ≤0.67 or ≥1.50 and False Discovery Rate 
(FDR) ≤0.05 after multiple hypothesis correction with Benjamini-Hochberg method. 
For study II, Affymetrix HTA 2.0 array was used, which includes more than six 
million probes and allows the identification of both coding and non-coding tran-
scripts. Further annotation of these probes through Ensembl BioMart [444] allowed 
the identification of the associated gene and transcript biotypes, on the bases 
of which we could select long non-coding RNAs only. Transcriptome Analysis 
Console (TAC) software (Thermo Fisher Scientific) was used for data analysis 
and transcripts with fold-change ≤0.67 or ≥1.50 and False Discovery Rate (FDR) 
≤0.05 were considered significantly differentially expressed. 
For study IV, Affymetrix Human Gene 2.0 ST Array provided complete gene 
expression profiling and Transcriptome Analysis Console (TAC) software was 
used to identify protein-coding transcripts having fold-change ≤0.77 or ≥1.30 and 
nominal P-value ≤0.05.
3.6 Next-generation sequencing
For study III, upon reverse transcription of the RNA samples into cDNA and test 
for the expression of few microRNAs and synthetic spike-in RNAs as quality 
control, these samples proceed to library preparation. Small RNA sequencing was 
performed at Qiagen Genomic Services, Germany, with the Illumina NextSeq500 
(Illumina). Next-generation sequencing analysis of small RNAs were conducted 
with using R (version 3.6.3, www.r-project.org/) and the Bioconductor (Release 3.9, 
www.bioconductor.org/) [445] package edgeR (version 3.26) [446]. MicroRNAs 
low in abundance were excluded from further analysis. To be included they had to 
have TPM (transcript per million) ≥5 in at least one of the two investigated cohorts. 
Significantly deregulated microRNAs passed the thresholds of fold-change ≤0.8 or 
≥1.2 and P-value ≤0.05. Exact test on the negative binomial distribution was used 
to determine the P-value for the significantly differentially expressed miRNAs.
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For study IV, small RNA next-generation sequencing was performed at Beijing 
Genomics Institute, China. Briefly, adaptor sequences were trimmed from fastq 
files and together with low-quality tags were removed from the sequencing data. 
Sequences (clean reads) were aligned to the reference human miRBase v.21 pre-
cursor dataset (www.mirbase.org/) [447]. Based on the length of 22-25 nucleotides 
and precursor analysis giving information about the secondary structure, novel 
microRNA transcripts were predicted using MIREAP tool (github.com/liqb/
mireap); these were then mapped to the human genome. Transcript Per Million 
(TPM) data normalization was followed by differential expression analysis of 
microRNAs, using R (version 3.6.3) and its Bioconductor (Release 3.10) pack-
age edgeR (version 3.14) [446]. Psoriasis lesional vs. healthy, psoriasis lesional 
vs. psoriasis non-lesional, and psoriasis non-lesional vs. healthy group compari-
sons were performed and the threshold for microRNAs selection was set to fold-
change ≤0.7 or ≥1.4 and false discovery rate (FDR) <10%. Besides these criteria, 
miRNAs, which had average 1 transcript per million (TPM) in at least one of the 
groups and which were expressed in at least half of the samples in any group were 
considered to be expressed.
3.7 Gene ontology and gene set enrichment analyses
Analysis of Gene Ontology Biological Processes (GO-BP) were performed for study 
I and IV using the online tool Enrichr (https://amp.pharm.mssm.edu/Enrichr) [448, 
449]. Similarly, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways 
analysis were performed for study I.  Moreover, in study I we performed Gene Set 
Enrichment Analysis (GSEA) (www.gsea-msigdb.org/gsea/) [450, 451] to identify 
which cytokine-responsive gene signatures were enriched in CD45-negative epi-
dermal cells from psoriasis lesional skin. We based this study on 36 experiments 
available in GEO (Gene Expression Omnibus) database (www.ncbi.nlm.nih.gov/
geo/), in which keratinocytes monolayer and 3D reconstructed epidermis were 
treated with different cytokines. We extracted the lists of genes up-regulated by 
the cytokines’ treatments having fold-change ≥1.5 and nominal P-value ≤0.05. 
Analysis were carried out using Gene Set Enrichment Analysis software (GSEA, 
powered by Broad Institute) [450].
3.8 Mapping genes in proximity of psoriasis-associated 
SNPs
For study I and II, we aimed to determine whether deregulated protein-coding or 
non-coding transcripts identified with microarray analysis were overlapping regions 
in proximity to SNPs (single nucleotide polymorphisms) associated to psoriasis 
susceptibility loci (PSORS). The genomic coordinates of psoriasis-associated 
SNPs were collected from four previous publications [101, 104, 452, 453]. We 
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then used the R based Bioconductor package “GenomicRanges” [454] to over-
lap the genomic coordinates of significantly deregulated protein-coding genes in 
study I, with a range of 500 Kbp (250 Kbp upstream and 250 Kbp downstream) 
from the exact genomic position of PSORS-associated SNPs. Similarly, due to the 
extensive length of long non-coding RNAs, in study II we calculated a range of 1 
Mbp (500 Kbp upstream and 500 kbp down-stream) from the exact genomic posi-
tion of PSORS-associated SNPs and we overlapped to this region the significantly 
differentially expressed long non-coding RNAs detected in our profiling study.
3.9 Analysis of transcription factor binding site motifs
In study I, the software MetaCoreTM (Thomson Reuters; Clarivate Analytics brand), 
which uses data from literature (predicted and validated), allowed us to determine 
the transcription factor binding motifs among the significantly deregulated genes 
in psoriasis lesion (PP) vs. healthy controls (H).
3.10 Cell culture, treatments and transfections
Normal human epidermal keratinocytes (NHEK) (Thermo Fisher Scientific, 
Catalog# C0055C) were cultured in 5% CO2 at 37 °C in EpiLife serum-free medium 
(Thermo Fisher Scientific) containing Human Keratinocyte Growth Supplement 
(HKGS) (Thermo Fisher Scientific) and penicillin/streptomycin (Thermo Fisher 
Scientific) antibiotics. Keratinocyte cultures between the third and fourth passage 
were used to perform all the experiments. When the keratinocytes’ monolayer 
reached about 70% confluence in 24-well plate, medium was removed and replaced 
with 0.5 ml of EpiLife serum-free medium (Thermo Fisher Scientific) in order to 
not affect further treatments and/or microRNA transfections.
In study I, NHEK were treated with recombinant Epigen (rEPGN) protein (Novus-
Biologicals (Bio-Techne brand), Catalog# NBP2-34987) at three different con-
centrations (50, 100, 200 ng/mL) and cell growth was determined with IncuCyte 
ZOOM® Live-Cell Analysis System (Essen BioScience, Sartorius brand), while 
area among the proliferating cells was analyzed with the IncuCyte ZOOM® soft-
ware (Essen BioScience, Sartorius brand). In study II, cells were treated with the 
cytokines IL-17A (100 ng/ml), IL-22 (20 ng/ml) and TNF-a (50 ng/ml) or with 
a combination of the three (R&D Systems, Bio-Techne brand) for 1, 3, 6, 24, 48, 
72 and 96 hours. In study IV, both monolayer of cultured keratinocytes and 3D 
reconstructed human epidermis were used. For RNA extraction and quantitative 
real-time PCR experiments, monolayer of keratinocytes were seeded in 24-well 
plates at a density of 40,000 cells/well. For western blotting, cells were seeded 
in 6-well plates at a density of 200,000 cells/well. Primary human keratinocytes 
in monolayer cultures were treated with IL-17A (100 ng/ml), IL-1β (10 ng/ml), 
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IL-36α (10 ng/ml), IL-22 (20 ng/ml), TNF-a (50 ng/ml), or a combination of 
IL-17A, IL-22 and TNF-a (R&D Systems, Bio-Techne brand). Keratinocytes 
were then transfected with 50 nM mirVana™ miRNA Inhibitor for miR-378a (to 
induce down-regulation) or Negative Control #1 (Thermo Fisher Scientific); or 1 
nM mirVana™ miRNA Mimic miR-378a (to induce overexpression) or Negative 
Control #1 (Thermo Fisher Scientific) using Lipofectamine 2000 (Thermo Fisher 
Scientific). Upon transfection, cells were treated with IL-17A (R&D Systems, 
Bio-Techne brand) at a concentration of 100 ng/ml and collected at different time 
points. To inhibit the NF-κB pathway, the anti-inflammatory compound BAY 
11-7082 (Sigma-Aldrich; Merck KGaA brand) –inhibitor of IκB kinase (IKK)– was 
used to treat monolayer cultures of NHEK at a concentration of 10 µM. Dimethyl 
sulfoxide (DMSO) was used as control. For C/EBP-β inhibition, a set of four pre-
designed short interference RNAs (siRNAs) for C/EBP-β gene (Dharmacon, Cat. 
#LQ-006423-00-0002) mixed together in a pool or siRNA Negative Control No. 
1 (Thermo Fisher Scientific) were transfected at a concentration of 30 nM using 
Lipofectamine 2000 (Thermo Fisher Scientific), following the manufacturer’s 
instructions. 
Three-dimensional (3D) reconstructed human epidermis (RHE) used in study IV 
were obtained from MatTek (Ashland) and cultured according to manufacturer’s 
instructions at the liquid-air interphase in hydrocortisone-free medium. IL-17A 
(20 ng/ml) (R&D Systems, Bio-Techne brand) was added to the cultured three-
dimensional epidermal equivalents for 72 hours. A different three-dimensional 
epidermal equivalent model was generated using primary normal human epidermal 
keratinocytes (NHEK) isolated from the epidermis of juvenile foreskin (same donor) 
and were kindly provided by our collaborator Prof. Bernhard Homey (Heinrich 
Heine University, Düsseldorf, Germany). 3D epidermal equivalents were treated 
with a mix of cytokines associated with psoriasis (IL-17A (30 ng/ml) + TNFα (5 
ng/ml) + IFNγ (20 ng/ml)) (R&D Systems, Bio-Techne brand) and collected 72 
h after treatment.
3.11 Quantitative real-time PCR
In study I, II, IV, for mRNAs, total RNA extracted from CD45-negative human 
epidermal cells, from keratinocytes monolayer, from 3D reconstructed human epi-
dermis and from mice skin biopsies was reverse transcribed using the RevertAidTM 
First Strand cDNA Synthesis Kit (Thermo Fisher Scientific). For microRNAs, total 
RNA was reverse transcribed using TaqMan MicroRNA Reverse Transcription Kit 
(Thermo Fisher Scientific) including primers for miR-378a and RNU48 (Thermo 
Fisher Scientific). TaqMan® PrimeTime predesigned primers for mRNAs were pur-
chased from Integrated DNA Technologies (IDT). Long non-coding RNAs TaqMan-
based primers for quantitative RT-PCR were design using the IDT PrimerQuest® 
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Tool (Integrated DNA Technologies) and were based on their transcripts’ sequences. 
QuantStudio 7 Flex Real-Time PCR System (Thermo Fisher Scientific) was used to 
quantitatively amplify the reverted cDNA. Normalization against the housekeeping 
gene 18S (18S, forward primer: CGGCTACCACATCCAAGGAA; reverse primer: 
GCTGGAATTACCGCGGCT, probe: TGCTGGCACCAGACTTGCCCTC) for 
human mRNAs and RNU48 for human miRNA miR-378a was calculated using the 
DDCt-method. Expression of mouse messengerRNAs were normalized against the 
averaged expression of the housekeeping genes Gapdh, B2m and Actb, and mouse 
microRNA miR-378a against the housekeeping gene Rnu6, with the DDct-method.
For study III, a volume of 2 μL of RNA was reverse transcribed in 10 μL reactions 
using the miRCURY LNATM Universal RT microRNA PCR, Polyadenylation and 
cDNA synthesis kit (Exiqon A/S, Qiagen brand). cDNA was then diluted 50X and 
analyzed in 10 μL PCR reactions according to the manufacturer’s protocol. Each 
microRNA was assayed once by RT-qPCR on the microRNA Ready-to-Use PCR 
custom Pick & Mix using ExiLENT SYBR® Green master mix (Exiqon A/S, 
Qiagen brand). Exclusion of the template from the reverse transcription reac-
tion was possible by performing negative controls, which were further profiled 
like the samples. The steps of amplification, detection and quantification were 
achieved in 384-well plates with a LightCycler® 480 Real-Time PCR System 
(Roche Diagnostics). Experiments were conducted at Qiagen Genomic Services, 
Germany. Haemolysis was monitored through the ratio of the expression of two 
microRNAs: miR-451a (expressed in red blood cells) and miR-23a-3p (relatively 
stable in serum and plasma and not affected by haemolysis), where a ratio above 
7.0 indicates an increased risk of being affected by haemolysis [455]. None of 
the samples needed to be excluded based on this criterion. MicroRNA expres-
sion values obtained by quantitative RT-PCR were normalized to the average of 
three microRNA normalizers (hsa-miR-191-5p; hsa-miR-320a; hsa-miR-423-3p). 
These were identified to be expressed with high stability across our samples by 
the NormFinder algorithm (update January 2015) [456]. Each miRNA Ct value 
obtained from quantitative RT-PCR analysis was converted in the corresponding 
expression level (ECqmiR = 2–Cq), and the relative expression units were calculated as 
DCqmiR(target) = ECqmiR(target) – mean(ECqmiR(normaliser1); ECqmiR(normaliser2)); ECqmiR(normaliser3)). 
Finally, difference in the levels of the target miRNAs among the two groups (PsA 
vs. PsC) was calculated as DDCqmiR = (DCqmiR(target) in PsA) – (DCqmiR(target) in PsC).
3.12 RNAscope in situ hybridization assay
In study II, 7 µm thick formalin-fixed (4%) paraffin-embedded (FFPE) skin sec-
tions from healthy volunteers and patients with psoriasis were used to perform the 
manual RNAscope® in situ hybridization assay. For the long non-coding RNA 
LINC00958, predesigned double Z (ZZ) probes were purchased from Advanced 
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Cell Diagnostics, Inc. (ACDBio; Bio-Techne brand, Cat. No. 478601). Briefly, 
skin sections were deparaffinised with X-TRA-Solv© and ethanol at different 
concentrations. To block endogenous peroxidase activity (Hydrogen Peroxide), 
reducing the background noise signal, we used the RNAscope® Pretreatment rea-
gents according to the manufacturer’s instructions (ACDBio; Bio-Techne brand), 
while to better access the RNA-target molecule we performed heat induced target 
retrieval and treatment of the sections with Protease Plus (ACDBio; Bio-Techne 
brand). LINC00958 and Negative Control (ACDBio; Bio-Techne brand, Cat. No. 
321831) probes were hybridized for 2 hours at 40 °C and three amplification steps 
(Amp1, Amp2, Amp3) were performed using RNAscope® Multiplex Fluorescent 
Reagent Kit v2 (ACDBio; Bio-Techne brand, Cat. No.  323100). Fluorescence 
detection was possible through probes labelling with TSA® plus fluorophore 
(PerkinElmer, Akoya Biosciences brand) and sections imaged with Confocal 
microscope Zeiss LSM 800 with Airyscan (Carl Zeiss).
3.13 Western blotting
In study IV, proteins were isolated from previously described transfected and 
treated cell cultures, using 60 µL lysis buffer. Analysis of western blotting were 
performed according to standard procedures using the following antibodies pur-
chase from CTS (Cell Signaling Technology): anti-IκBα (mouse monoclonal, 
1:1000, Cat. #4812), anti-phospho-IκBα (rabbit monoclonal, 1:1000, Cat. #2859). 
HRP-coupled β-Actin (1:20000) (Merck KGaA) was used as a loading control. 
The anti-rabbit secondary antibody (Cell Signaling Technology) was used follow-
ing the manufacturer’s instructions. The anti-rabbit IgG (Cell Signaling) served 
as negative control. Horseradish peroxidase-coupled isotype-specific anti-rabbit 
secondary antibodies were purchased from Dako (Agilent). Enhanced chemilu-
minescence detection system allowed the detection of the immune complexes 
according to the manufacturer’s protocol (GE Healthcare).
3.14 Mice and the IMQ (imiquimod)-induced mouse 
model of psoriasis
In study IV, wild-type C57BL/6J mice were procured from Charles River. 5-7 µg 
of miR-378a mimic or scrambled control (mirVana) were injected intradermally 
into the shaved back skin of female C57BL/6J mice at 8 weeks of age to over-
express miR-378a. The mimic injection was reinforced by the transfection agent 
Max Suppressor In Vivo RNA-LANCEr II (Bio Scientific) and it was repeated at 
days 1, 2 and 3. At the same time of the repeated mimic injection (day 1, 2 and 3), 
a topical dose of 62.5 mg (5%) of Aldara cream (imiquimod/IMQ, Aldara cream; 
Meda Pharmaceuticals) was applied on the shaved back skin of the mice for 3 
consecutive days and sacrificed at day 4, while control mice were treated with 
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the same amount of vehicle cream. Skin thickness was measured with a Vernier 
caliper (AgnTho’s AB) and clinical scores were assessed by three independent 
researchers to assign a score of 0 to 4 (0, none; 1, mild; 2, moderate; 3, severe; 
and 4, very severe) for erythema, scaling, and thickness.
3.15 Histology and immunohistochemistry
In study IV, back-skin samples from mice were collected at the end of the experi-
ments were fixed in neutral formalin. Seven µm paraffin-embedded sections were 
made and stained with the dyes haematoxylin and eosin (H&E) and epidermal 
thickness was measured using ImageJ (Fiji) software [457]. Analysis of cell pro-
liferation was performed with immunostaining of anti-mouse Ki-67 marker (Cell 
Signaling Technology (CST), #12202) with rabbit as host species. Briefly, upon 
deparaffinization with X-tra Solv and ethanol, sections were incubated with Tris-
EDTA buffer at 98 °C for 25 min to unmask the proteins. Hydrogen peroxidase 
(H2O2) at 0.3% concentration was applied for 15 min at room temperature (RT) in 
the dark. 10% normal blocking goat serum diluted in 1% BSA in PBS was applied 
for 45 min at RT, followed by overnight incubation at 4 °C with primary antibodies 
Ki-67 and rabbit IgG isotype control (Cell Signaling Technology (CST), #3900), 
both diluted 1:200 in 1% BSA in PBS. The following day, sections were incu-
bated with anti-rabbit biotinylated secondary antibody (Cell Signaling Technology 
(CST), #14708) diluted 1:200 in 1% BSA in PBS for 45 min. Detection was pos-
sible using Vectastain ABC and AEC Peroxidase (HRP) Substrate Kit (Vector 
Laboratories). Number of positive cells/field of view was quantified using Fiji 
(ImageJ) software [457].
3.16 Statistical analysis
Most of the statistical analyses across all the experiments we’ve performed in 
study I, II, III, IV, were conducted using IBM SPSS Statistics for Mac ver. 25.0 
(IBM Inc.), R software ver. 3.5.1 to 3.6.3 (R Foundation for Statistical Computing, 
Vienna, Austria) and GraphPad Prism ver. 7.0a to 8.3.1 for Windows (GraphPad 
Software).
In particular, for study III, Spearman’s correlation test was also used to determine 
the correlation between the significantly differentially expressed microRNAs let-
7b-3p/miR-30e-5p in the two cohorts PsC/PsA, as well as their correlation with 
the psoriatic arthritis disease-related scores (PASI, DAS28, BASDAI, number 
of swollen and tender joints). To estimate the association between microRNA 
levels in plasma extracellular vesicles and the presence of arthritis, univariate 
and multivariate logistic regression analyses were performed. Receiver operating 
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 characteristics (ROC) curves and area under the curve (AUC) assessed the accu-
racy of the classification of patients with and without the arthritis manifestations.
For different experiments, Mann-Whitney U test, Student’s t-test or two-way 
ANOVA were used to determine significant difference between groups. P-values 
<0.05 were considered to be statistically significant. *P <0.05; **P <0.01; ***P 
<0.001 and ****P <0.0001. Statistical analysis of microarray and RNA-seq data 
is described at the relevant sections in detail.
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4 RESULTS AND DISCUSSION
The population of cells on which our studies were focused the most are CD45-
negative cells isolated from the epidermis of patients with psoriasis, as well as 
from healthy donors. This population contains mainly keratinocytes and this 
approach allowed us to investigate keratinocyte-specific transcriptomic changes 
and exclude changes coming from immune cells, which are CD45-positive. The 
procedure leading to the isolation of CD45-negative epidermal cells from skin 
punch biopsies is illustrated in Figure 16.
Figure 16. CD45-negative epidermal cell sorting from 4 mm punch skin biopsy. Pictures 
adapted from https://www.mayoclinic.org/tests-procedures/skin-biopsy/about/pac-20384634.
4.1 Keratinocyte-specific protein-coding transcriptome 
of psoriasis skin
In order to better characterize the contribution of keratinocytes in the altered 
transcriptome of psoriasis, we used sorted CD45neg epidermal cells from psoriasis 
lesion (PP = 9), psoriasis non-lesion (PN = 9) and healthy donors (H = 9), in which 
dermal cells, as well as immune cells, were depleted. The approach we adopted is 
what makes our study unique compared to others, where full-depth skin biopsies 
[458-461] or epidermal sections obtained by laser capture microdissection [462] 
were used to perform psoriasis transcriptomic profiling studies.
4.1.1 Transcriptomic profiling of keratinocytes in psoriasis
Principal component analysis (PCA) in Figure 17a have shown separation of the 
CD45neg cells from the three groups in consideration (PP, PN, H), with keratino-
cytes from the psoriasis lesion group that clearly dissociates from the non-lesional 
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and healthy ones. This was confirmed at the transcriptome level, where we have 
identified most of the changes in the PP vs. H group comparison (Figure 17b), 
with 2,365 genes with significantly altered expression (1,629 up- and 736 down-
regulated) (Figure 17c-d). In lesional (PP) vs. non-lesional (PN) psoriasis, 1188 
up- and 388 down-regulated genes were identified (Figure 17d), while just 36 
significantly altered genes were found in PN vs. H group comparison (Figure 
17d). Despite the relatively small number of altered genes found in non-lesional vs. 
healthy epidermal cells, this could suggest a “pre-psoriatic” state in the keratino-
cytes of the psoriasis non-lesional skin.
Figure 17. Transcriptomic changes in psoriatic keratinocytes. (a) Principal component 
analysis of deregulated genes in sorted CD45neg epidermal cells from PP, PN, H. (b) 
Volcano plot showing the log2(fold-change) for the identified transcriptomic changes. (c) 
Heatmaps for the top 50 up- and 50 down-regulated genes in PP vs. H group comparison. 
(d) Graph illustrating the number of deregulated transcripts –in blue down-regulated 
genes; in red up-regulated genes. Venn-diagram showing the extent of overlapping genes 
with fold-change >1.5 between the three groups. PP = psoriasis lesional keratinocytes, 
PN = psoriasis non-lesional keratinocytes, H = healthy keratinocytes, FC = fold-change. 
Reproduced and adapted with permission from Pasquali L et al, 2019; Copyrights© Acta 
Dermato-Venereologica.
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4.1.2 Enrichment and signature dominance of deregulated genes 
in psoriatic keratinocytes
The altered gene expression found in psoriasis keratinocytes compared to healthy 
skin were enriched in pathways related to cellular proliferation, with potential con-
tributors such as the previously uncharacterized gene Epithelial Mitogen (EPGN) 
[463], but also to innate immunity and response to inflammatory processes, such 
as type I interferon signature (IFI44, IFI44L and DDX60 genes), NF-kB signaling 
pathway and DNA replication. This was consistent with previous studies exploring 
the transcriptome changes in full-depth skin biopsies [460, 461]. Moreover, genes 
previously thought to belong exclusively to immune cells, such as the negative 
regulator of NF-kB signaling pathway TNIP3 (alternatively known as ABIN-3) in γδ 
T cells [458], were identified in this study with altered expression in keratinocytes.
In particular, up-regulated gene in PP vs. H epidermal cells comparison, have shown 
enrichment in gene ontology terms related to keratinocytes development and dif-
ferentiation, while down-regulated transcripts had enrichment in skin epidermis 
development. Pathways related to tight junctions and transforming growth factor 
beta (TGF-β) were the most significant KEGG pathways found for this group 
comparison. Similar pathways and gene ontology enrichment were found analyz-
ing the transcriptomic changes in lesional vs. non-lesional keratinocytes. All these 
reflected a clear predisposition for altered differentiation in psoriatic keratinocytes.
The skin inflammation in psoriasis is driven by an over-production of pro-inflam-
matory cytokines from T cells infiltrating the epidermis. To understand which 
pro-inflammatory component had the biggest impact on the keratinocytes-specific 
transcriptome alterations, we performed Gene Set Enrichment Analysis (GSEA) 
using 36 publically available lists of genes up-regulated in cultured primary human 
keratinocytes and epidermal equivalents (GEO database). We have found that dif-
ferentially expressed genes in PP vs. H had the most significant enrichment within 
the list of genes over-expressed by IL-17 and IL-22 treatment of primary human 
keratinocyte cell cultures, as well as by IL-20 subfamily and IL-1a, IL-36, TNF-
a, IFN-g (Figure 18a). These results are in line with studies showing that Th17 
cells secreted cytokines, IL-17, and IL-22, in synergy with IFN-g and TNF-a, 
are central players in the psoriasis pathogenesis [88, 464]. Despite this, we have 
also found that just nearly 50% of the overexpressed genes in psoriasis lesional 
keratinocytes compared to healthy overlapped with cytokines-related induced 
gene lists, among which genes induced by IFN-g have the highest proportion of 
overlap, followed by IL-22 and IL-17A. This suggests that the remaining 50% 
represents intrinsic changes in the epidermis of psoriasis, which do not depend on 
the cytokines’ inflammation (Figure 18b).
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Figure 18. IL-17 and IL-22 gene signatures dominates the transcriptomic changes in psori-
atic keratinocytes. (a) Gene Set Enrichment Analysis of 36 cytokines-induced gene lists and 
up-regulated genes in psoriatic keratinocytes compared to healthy. (b) up-regulated genes in 
psoriatic keratinocytes compared to healthy which are (dark green) or are not (light green) 
overlapping with any of the 36 cytokines-induced gene lists. (c) Proportion of significantly 
up-regulated genes by each cytokine/growth factor across all the overexpressed genes in 
psoriatic keratinocytes compared to healthy. PP = psoriasis lesional keratinocytes, H = 
healthy keratinocytes, DEGs = differentially expressed genes. Reproduced and adapted 
with permission from Pasquali L et al, 2019; Copyrights© Acta Dermato-Venereologica.
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4.1.3 Altered genes in psoriatic epidermis may contribute to its 
genetic susceptibility
To understand the impact of the genetic component on the altered expression of 
transcripts in psoriatic keratinocytes, we overlapped the genomic coordinates of 
significantly deregulated transcripts in PP vs. H comparison, with regions nearby 
single nucleotide polymorphisms (SNPs) known to be associated to the susceptibil-
ity of psoriasis from previous GWAS studies [101, 104, 453, 465]. A total of 107 
deregulated genes in psoriatic lesional vs. healthy keratinocytes were overlapping 
regions spanning the psoriasis-associated SNPs for 250 kbp up- and downstream, 
therefore being in close proximity. In lesional vs. non-lesional psoriatic keratino-
cytes 89 DEGs were overlapping SNPs associated to psoriasis susceptibility and 
only 2 in the non-lesional vs. healthy keratinocytes comparison (Figure 19). These 
results could partially explain the previously discussed 50% of alterations which 
are not associated to the cytokine milieu but that might be rooted in the genetic 
predisposition of psoriasis lesional keratinocytes.
The majority of these genes overlapping psoriasis-susceptibility SNPs were local-
ized on chromosome 1, where the epidermal differentiation complex (EDC) [121] 
and the psoriasis susceptibility locus PSORS4 [466] reside. Few examples are the 
well-known late cornified envelope (LCE) genes [121], TNFAIP3 (regulator of 
NF-kB signalling) [467] and the top down-regulated in our list C1orf68 (XP32) 
[468]. In addition, we have identified differentially expressed genes with unknown 
previous characterization in psoriasis overlapping genomic regions in proximity 
of psoriasis-susceptibility SNPs.
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Figure 19. Distribution across chromosomes of the differentially expressed genes in psori-
atic lesional vs. healthy keratinocytes comparison. In red is shown the proportion of genes 
overlapping psoriasis-associated SNPs. Known PSORS (psoriasis susceptibility loci) are 
reported above the respective chromosome where they belong to. Reproduced and adapted 
with permission from Pasquali L et al, 2019; Copyrights© Acta Dermato-Venereologica.
4.1.4 Transcription factors can act as upstream regulator of 
differentially expressed genes in psoriatic keratinocytes
Performing analysis of transcription factor binding sites of the differentially 
expressed genes in psoriatic lesional vs. healthy keratinocytes, we have deter-
mined a total of 338 transcription factors, of which 54 had altered expression at the 
mRNA level in the psoriatic lesional keratinocytes. Among these, we have found 
known TFs related to inflammation and epidermal differentiation –AP-1 subunits, 
important for the activation of cytokines expression in keratinocytes, followed by 
attraction of neutrophils and macrophages in the epidermis, leading to the typi-
cal psoriasis phenotypic alterations [250] and transcription factors associated to 
NF-kB such as SOX4, KLF4, GATA3 and STAT1-3 [101], some of which have 
genomic location nearby PSORS-associated SNPs. Moreover, TRPS1, HEY2 and 
PAX3 are examples of TFs not characterized in the context of the disease yet, as 
well as FOXO1, previously thought to play roles in T cells only, now shown as 
differentially expressed in psoriatic lesional keratinocytes. Finally, the transcrip-
tion factor NR4A3, which has been detected as one of the most down-regulated 
genes in psoriasis non-lesional compared to healthy keratinocytes in our study, 
was not identified as altered in previous psoriasis transcriptomic profiling studies.
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4.2 Long non-coding RNA landscape of psoriasis 
keratinocytes
Long non-coding RNAs represent a relatively new field of study, which becomes 
even newer when it comes to investigate it in an inflammatory disease such as 
psoriasis. In addition, virtually nothing is known about the role of lncRNAs in 
keratinocytes alterations during psoriasis onset and/or progression. In this study, 
we selected the non-coding transcriptome from the previously sorted CD45neg 
epidermal cells from psoriasis lesion/non-lesion and healthy donors, filtered for 
transcripts longer than 200 nucleotides and we inspected the differences in their 
expression levels across the three groups. Once more, we excluded the immune 
cells component known to infiltrate the epidermis of psoriasis patients [38], that 
could have masked the real expression of the keratinocytes-specific non-coding 
transcriptome.
4.2.1 Profiling of psoriasis CD45neg cells identifies altered long 
non-coding RNAs adjacent to psoriasis susceptibility loci
Our previous microarray study profiling of the keratinocytes transcriptome in 
psoriasis has shown substantial changes in the expression of messenger RNAs 
[130]. As expected, when reducing the dimensionality of the non-coding tran-
scriptome data through principal component analysis (PCA), a clear segregation 
of the psoriasis lesional from the psoriasis non-lesional and healthy samples was 
identified (Figure 20a), with the majority of the alterations residing in the CD45neg 
cells of psoriasis lesion (PP) vs. healthy donors (H) (Figure 20b). We decided to 
focus our study on the lincRNA (long intergenic non-coding RNA) class, due to 
their more established database annotation, as well as their potential role in the 
immune system development and function and common features with mRNAs 
[469, 470]. A total of 80 deregulated lincRNAs (43 up- and 37 down-regulated) 
were found comparing psoriatic lesional (PP) vs. healthy (H) epidermal cells 
(fold-change >1.5 and P-value <0.05). Comparing lesional (PP) vs. non-lesional 
(PN) psoriasis samples we have identified 65 deregulated lincRNAs (26 up- and 
39 down-regulated) with the same fold-change and significance threshold criteria, 
while 2 up- and 2 down-regulated lincRNAs were found with altered expression 
levels in psoriasis non-lesion (PN) vs. healthy skin samples. Among these, we suc-
cessfully identified lncRNAs previously known as altered in their expression in 
psoriasis, such as PRINS [418], in addition to lncRNAs which expression levels 
were found to be not changed in studies including full-depth skin samples [471]. 
An example is the lncRNA NEAT1.
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Figure 20. (a) Principal component analysis of the long non-coding RNA (lncRNA) tran-
scriptome of CD45neg epidermal cells from psoriasis lesional (PP, red) and non-lesional 
(PN, green) skin and skin from healthy controls (H, blue). (b) Volcano plot showing the log2 
fold-change and the nominal P-value threshold at 0.05 (horizontal line) for the lncRNAs. 
Blue and red color indicates transcripts differentially expressed with fold-change <0.5 
and >2.0, respectively.
Further analysis of the genomic localization of the deregulated lncRNAs in our 
profiling study were intended to identify potential non-coding RNA players in the 
genetic of psoriasis. Genomic coordinates of significantly differentially expressed 
lncRNAs in our analysis were matched with coordinates from a 1 Mbp range 
across psoriasis-susceptibility SNPs (see Materials and Methods section) to iden-
tify potential overlaps. A total of 32 differentially expressed lncRNAs were found 
overlapping psoriasis-susceptibility SNPs in our profiling study. From these, 11 
lncRNAs were deregulated exclusively in PP vs. H CD45neg cells comparison, 
11 differentially expressed exclusively in PP vs. PN comparison, while 10 were 
deregulated in both group comparisons. Several deregulate lncRNAs were overlap-
ping SNPs on chromosome 6p21.3, where PSORS1 and the major histocompat-
ibility complex (MHC) are located [472]. This region includes the main psoriasis 
risk allele HLA-C*06:02, which plays an essential role in the complex genetic 
predisposition of the disease [102]. In addition, several differentially expressed 
lncRNAs were found overlapping PSORS4 [473], together with genes involved in 
differentiation and cornification of the keratinocytes comprised in the epidermal 
differentiation complex (EDC) [121] on chromosome 1q21 (Figure 21). Taken 
together, these results denote the potential role of keratinocytes-specific lncRNAs 
in the genetic predisposition of psoriasis.
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Figure 21. Genomic localization of deregulated lncRNAs in psoriasis lesional, non lesional 
and healthy CD45neg sorted cells. In red the proportion of lncRNAs in proximity of psoriasis-
susceptibility SNPs within their respective chromosome regions. H, healthy; PN, psoriasis 
non-lesion; PP, psoriasis lesion.
4.2.2 Epithelial tissue enriched LINC00958 is upregulated in pso-
riatic keratinocytes, with primarily cytoplasmic localization
LINC00958 was selected for further validation, since it was one of the top over-
expressed lincRNAs in psoriasis lesional keratinocytes compared to healthy (fold-
change = 2.14) in our microarray analysis (Figure 22a). Following RT-qPCR 
analysis confirmed the increased LINC00958 expression in isolated CD45neg cells 
from psoriasis lesional, compared to paired non-lesional (fold-change = 2.24) and 
healthy skin samples (fold-change = 2.6) (Figure 22b). Interestingly, we did not 
find alterations of LINC00958 expression in cultured primary human keratinocytes 
treated with the pro-inflammatory cytokines IL-17A, IL-22, TNF-a, commonly 
found in psoriasis. This suggests the presence of other elements that could drive 
the up-regulation of this lincRNA in psoriasis lesions.
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Figure 22. Affymetrix microarray (a) and RT-qPCR (b) gene expression analysis for 
LINC00958 in CD45neg cells isolated from psoriasis lesion (PP), non-lesion (PN) and 
heathy (H) skin samples. H, healthy; PN, psoriasis non-lesion; PP, psoriasis lesion. RPKM, 
reads per kilobase per million reads. *P <0.05, **P <0.01, ***P <0.001, ****P <0.0001.
LINC00958, uncharacterized in the context of psoriasis at the time of writing, has 
been found linked to other diseases in different tissues (e.g. bladder cancer) [474-
478]. In addition, we have determined the absence of protein coding potential for 
LINC00958 through different available algortithms, such as CPAT [479], CPC 2.0 
[480], PORTRAIT [481] and PhyloCSF [482] (Figure 23a), and we have identified 
tissues with stratified squamous epithelia (such as the skin) as those with highest 
enrichment for this lncRNA (Figure 23b).
Figure 23. (a) LINC00958 protein-coding potential. (b) Expression of LINC00948 across 
27 tissues from 95 normal human samples. CPAT, Coding Potential Assessing Tool; CPC, 
Coding Potential Calculator 2; PROTRAIT, Prediction of Transcriptomic ncRNA by Ab 
Initio Methods.
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Using RNA-seq mapping reads from ENCODE database, we have determined 
peaks corrisponding to enrichment in genomic regions for LINC00958 in dif-
ferent cell types. Its expression was limited to keratinocytes, while melanocytes, 
fibroblasts, adipose tissue and even immune cells (CD4+ and CD8+ T cells) show 
low or absent expression. This suggests that the overexpression of LINC00958 
in psoriasis lesion is due to its increased levels in keratinocytes. This could also 
explain why LINC00958 expression was not detected as altered in previous non-
coding RNA profiling studies in psoriasis [471].
Finally, using RNAscope in situ hybridization technique on psoriasis skin sections, 
we have identified the enrichment of LINC00958 mainly in the cytoplasm (Figure 
24), with just sporadic single molecules detected at the nuclear level. This, as in 
general for cytoplasmic lncRNAs, could suggest a potential role of the lncRNA 
in for example regulating the stability or the translation of other mRNAs, as well 
as binding and interacting with certain proteins. Further functional studies of 
this and other differentially expressed lncRNAs in psoriatic keratinocytes could 
unveil their contribution in the epidermal homeostasis imbalance as well as in the 
development of the disease.
Figure 24. RNAscope in situ hybridization detection of LINC00958 at the single molecule 
level in psoriasis lesional skin sections. Dapi nuclei stained in blue; LINC00958 single 
molecules stained in orange.
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4.3 Plasma-derived extracellular vesicles microRNAs 
as biomarkers for psoriatic arthritis in patients with 
psoriasis
As discussed in the introductory chapter of this thesis, psoriasis is rich in several 
comorbidities, among which the most common is psoriatic arthritis (PsA). This 
affects approximately 1/3 of the patients with cutaneous psoriasis, with mani-
festations visible on average no earlier than ten years from the diagnosis of the 
cutaneous psoriasis symptoms [483]. Because of the challenging diagnosis, it is 
estimated that up to 15% of the patients with psoriasis have undetected psoriatic 
arthritis [225]. Intergluteal psoriasis and nail changes clinical markers for psoriatic 
arthritis [233] do not result in an accurate prediction of disease onset. IL-6 and 
CXCL10 as soluble biomarkers [234, 235] as well as a genetic signature [484] 
have been proposed for assessing the risk of psoriatic arthritis onset in patients 
with cutaneous psoriasis. Despite the effort, at the time of writing, no consistent 
biomarkers for a clear detection of PsA are available in clinical practice.
New evidences have reported the ability of some cells to secrete miRNAs in extra-
cellular vesicles (EVs) [485], creating a communication network between distant 
cells [486]. With this study we highlighted the role of circulating microRNAs in 
extracellular vesicles, as potential markers to distinguish cutaneous psoriasis patients 
predisposed to the development of psoriatic arthritis, from those who are not.
4.3.1 Next-generation sequencing identifies changed microRNAs 
levels in plasma extracellular vesicle of psoriatic arthritis 
patients
The study population comprised patients with cutaneous psoriasis which were fol-
lowed up for about 10 years. At the ten years follow up first visit, a dermatologist 
established the progression of the diseases in absence of subjective joint pain. In 
patients with subjective joint symptoms, a second visit was done by a rheumatolo-
gist, assessing for PsA. This allowed the classification of 29 patients without joint 
symptoms as cutaneous-only psoriasis (PsC) and 28 patients with simultaneous 
cutaneous psoriasis and joint symptoms as psoriatic arthritis (PsA) (Figure 25). 
At the time of sample collection, none of the patient were on systemic treatments 
that could have influenced the circulating miRNAs levels.
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Figure 25. Flowchart showing the selection criteria for patients grouping and the timeline 
for collecting the samples. Reproduced and adapted with permission from Pasquali L et 
al, 2020; Copyright© 1999-2020 John Wiley & Sons.
In the discovery phase, we performed small RNA-sequencing on plasma samples 
from 14 cutaneous-only psoriasis (PsC) and 15 psoriatic arthritis (PsA) patients 
(see Materials and Methods section). After filtering the NGS data for microRNAs 
having TPM >5 in at least one of the two cohorts, we have identified 151 miRNAs 
with stable expression in circulating extracellular vesicles (Figure 26a). Applying 
filters for absolute fold-change >1.2 and P-value <0.05 we have found 19 miRNAs 
with significantly altered levels in extracellular vesicles (9 with increased and 10 
with decreased levels) (Figure 26b).
Figure 26. (a) Volcano plot showing miRNAs with down-regulated (blue) and up-regulated 
(red) levels in circulating EVs. (b) Table of the significantly altered miRNAs detected in 
our NGS analysis. Reproduced and adapted with permission from Pasquali L et al, 2020; 
Copyright© 1999-2020 John Wiley & Sons.
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4.3.2 The miRNAs let-7b-5p and miR-30e-5p are potential 
biomarkers for psoriatic arthritis
We selected 41 miRNAs for validation with a RT-qPCR panel array; 15 miRNAs 
from the previous NGS analysis and 26 which have shown relevance in psoriasis, 
psoriatic arthritis and/or inflammation of the joints in previous publications [487-
491]. In this validation phase, both patients’ cohorts were extended, with a total 
of 29 PsC samples (including the 14 from the previous discovery phase) and 28 
PsA samples (including the 15 of the discovery phase). RT-qPCR analysis have 
reported the levels of miRNAs let-7b-5p and miR-30e-5p being significantly lower 
in patients with psoriatic arthritis (PsA) compared to those with cutaneous-only 
psoriasis (PsC) (Figure 27).
Figure 27. Violin plot showing RT-qPCR analysis reults for the miRNAs let-7b-5p and 
miR-30e-5p circulating in EVs of PsC and PsA samples (extended cohorts). PsA, psoria-
sis with psoriatic arthritis; PsC, cutaneous-only psoriasis. *P < 0.05, Mann–Whitney U 
test. Reproduced and adapted with permission from Pasquali L et al, 2020; Copyright© 
1999-2020 John Wiley & Sons.
In order to determine whether these microRNAs could be relevant markers for the 
diagnosis of psoriatic arthritis, we performed logistic regression analysis. Both 
let-7b-5p and miR-30e-5p have shown a significantly inverse association between 
their levels and the increased risk of developing arthritis manifestations in patients 
with cutaneous psoriasis (odds ratio = 0.270 for let-7b-5p; odds ratio = 0.255 for 
miR-30e-5p) (Figure 28a). Even after adjusting for variables like sex, age and 
PASI score, the inverse associations remained significant. Finally, ROC curves 
determined significant sensitivity/specificity for let-7b-5p (AUC = 0.68, P <0.05) 
and miR-30e-5p (AUC = 0.69, P <0.05) (Figure 28b), confirming the potential of 
these miRNAs in distinguish between the two study cohorts PsC and PsA.
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Figure 28. (a) Bivariate logistic regression analysis results illustrating the association 
between the circulating miRNAs let-7b-5p and miR-30e-5p and the psoriatic arthritis 
manifestations in patients with cutaneous pdoriasis. (b) ROC curves plotting sensitivity/
specificity for the extracellular vesicles levels of let-7b-5p and miR-30e-5p. PsA, pso-
riasis with psoriatic arthritis; PsC, cutaneous-only psoriasis; ROC, Receiver Operating 
Characteristic; AUC, Area Under the Curve; OR, Odds Ratio; C.I., confidence interval. 
Reproduced and adapted with permission from Pasquali L et al, 2020; Copyright© 1999-
2020 John Wiley & Sons.
In agreement with our findings, miRNA let-7b-5p has been found targeting directly 
the pro-inflammatory cytokine IL-6 [492], which is known to be over-expressed 
in psoriatic arthritis patients compared to patients with cutaneous-psoriasis only 
[493]. Other targets of let-7b-5p are associated to joint inflammation [494, 495], 
osteoclasts formation and bone loss [496, 497], indicating a potential role of this 
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miRNA in the pathogenic context of psoriatic arthritis. The miRNA miR-30e-5p 
was found to be down-regulated in PBMC of rheumatoid arthritis patients compared 
to healthy controls [498] and directly inhibiting BMI1, an activator of NF-kB-
signaling pathway that promotes arthritis-like symptoms in mice models [499, 500]. 
Despite the relatively small number of samples that could reduce the statistical 
power of our analysis, we successfully validated two miRNAs with significantly 
lower levels in EVs of PsA compared to PsC patients, avoiding results biases 
by selecting patients not undergoing systemic treatments. Further studies could 
determine whether reduced levels of let-7b-5 and miR-30e-5p in circulating EVs 
of PsA patients promote joint inflammation and, therefore, contribute to the patho-
genesis of the disease.
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4.4 Role and function of miR-378a in psoriatic 
keratinocytes
In order to further characterize the role of keratinocytes in the pathogenesis of 
psoriasis, our group has previously identified microRNAs differentially expressed 
between epidermal cells from psoriasis lesional and non-lesional skin, as well 
as from skin of healthy volunteers [131]. The microRNA miR-378a (has-miR-
378a-3p) was found as one of the top over-expressed in CD45neg cells (mainly 
keratinocytes) from lesional psoriasis, compared to paired psoriasis non-lesional 
samples and healthy controls [131]. This microRNA is localized on chromosome 
5 in human, within the intron of its host gene PPARGC1β [501]  and has conser-
vation on chromosome 18 in mice [502].
4.4.1 miR-378a confirmed up-regulation in psoriatic lesional 
keratinocytes
From previous NGS analysis, miR-378a was detected significantly up-regulated 
in PP (psoriasis lesion) compared with PN (psoriasis non-lesion) keratinocytes, 
with a fold-change of 2.83, while in PP compared to H (healthy skin) keratino-
cytes with a fold-change of 3.69 (Figure 29a). RT-qPCR analysis confirmed the 
over-expression of miR-378a in keratinocytes from psoriasis lesion compared to 
psoriasis non-lesion (fold-change = 2.33) and healthy (fold-change = 2.42) skin 
(Figure 29b).
Figure 29. (a) small RNA-sequencing and (b) RT-qPCR expression analyses of miR-378a 
in sorted CD45neg cells (mainly keratinocytes) from psoriasi lesional, non-lesional and 
healthy skin. H, healthy; PN, psoriasis non-lesion; PP, psoriasis lesion.
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4.4.2 miR-378a enhances skin inflammation when locally 
injected in imiquimod-induced mouse model of psoriasis
Having found altered expression of miR-378a in psoriatic keratinocytes, we aimed 
to investigate further its role in the disease. We therefore injected miR-378a mim-
ics in the intradermal layer of mice back skin, followed by topical application of 
imiquimod cream (IMQ, Aldara), known to induce psoriasis-like inflammation 
[259] (Figure 30a). Mice injected with miR-378a mimics and treated with IMQ 
cream were compared to mice injected with control oligos and treated as well with 
IMQ cream. Upon injection of miR-378a + IMQ application, mice have shown 
increased skin thickness (Figure 30b), as well as increased erythema and scaling 
(Figure 30c, macroscopic pictures), all evidences of ongoing inflammatory pro-
cesses in the skin, typically found in psoriasis. An increased epidermal thickness 
was found analyzing skin sections from mice miR-378a mimic injected + IMQ 
compared to control oligos injection + IMQ (Figure 30c, H&E staining). In this 
group comparison, also increased number of cells in the basal layer expressing the 
proliferation marker Ki67 were detected in miR-378a mimic + IMQ mice com-
pared to the control mice (Figure 30c, Ki67 staining). Finally, pro-inflammatory 
cytokines including Cxcl1, Ccl20, Il-17c and the psoriasis-associated marker 
Krt16 were enhanced upon injection of miR-378a mimics and topical treatment 
with imiquimod cream (Figure 30d). These results support the potential role of 
miR-378a in the induction of skin inflammation in psoriasis by reproducing a 
psoriasis-like phenotype in mice.
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Figure 30. (a) Timeline for injection of miR-378a mimic or control oligos before imiqui-
mod topical treatment on the shaved back skin of mice. (b) Measurement of skin thickness 
upon miR-378a mimic injection and IMQ topical treatment (orange) compared to control 
oligos injection and IMQ application (purple). (c) Quantitative RT-PCR analysis of Cxcl1, 
Ccl20, Il-17c and Krt16 expression in back skin from mice samples. Scale bar = 50 µm. * 
P<0.05, ** P<0.01, and *** P<0.001; n=6/group.
4.4.3 miR-378a is regulated by IL-17A via NF-kB and C/EBP-β in 
primary human keratinocytes
We aimed to identify potential regulators of miR-378a by treating cultured primary 
human keratinocytes with known psoriasis-associated pro-inflammatory cytokines. 
RT-qPCR results have shown that expression levels of both pri-miR-378a and its 
mature form miR-378a were increased upon IL-17A treatment of keratinocytes 
monolayer cultures (Figure 31a). The increased expression of miR-378a compared 
to untreated control was significantly higher at 24 h after IL-17A treatment, increas-
ing even more at 48 h, suggesting direct transcriptional induction of miR-378a by 
the cytokine IL-17A. Similarly, we have found overexpression of miR-378a also 
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in 3D epidermal reconstructs treated with IL-17A (Figure 31b) or treated with a 
combination of IL-17A, TNF-a and IFN-g (Figure 31c), cytokines commonly 
found in psoriasis lesional skin.
miR-378a shares the transcription starting site (TSS) location with its host gene 
PPARGC1β [290]. At this level, while further investigating the IL-17A pathway, 
we have found binding sites for the transcription factors NF-κB and C/EBP-β. 
We tested whether these TFs were playing a role in the regulation of miR-378a by 
blocking NF-κB signaling pathway with the inhibitor BAY 11-7082 or inhibiting 
C/EBP-β with a pool of specific siRNAs, in cultured monolayer of keratinocytes. 
The expression levels of miR-378a were reduced when NF-κB inhibition was 
followed by treatment of IL-17A, while no expression changes were detected for 
miR-378a in absence of IL-17A treatment (Figure 31d). Alternatively, inhibition 
of miR-378a upon interruption of C/EBP-β signaling pathway was independent 
of IL-17A treatment (Figure 31e). Overall, we confirmed the importance of these 
TFs in promoting inflammatory responses through the regulation of miR-378a 
expression.
Figure 31. (a) RT-qPCR analysis of pri-miR-378a and miR-378a expression in cultured 
primary human keratinocytes treated with IL-17A at different time points. (b) RT-qPCR 
analysis of miR-37a in 3D epidermal reconstruct treated with IL-17A for 72 h. (c) RT-qPCR 
analysis of miR-37a in 3D epidermal reconstruct treated with a combination of IL-17A+ 
TNF-a and IFN-g for 72 h. (d) RT-qPCR analysis of miR-378a upon NF-κB signaling path-
way inhibition by BAY11-7082, in presence or absence of IL-17A treatment. (e) RT-qPCR 
analysis of miR-378a in cultured keratinocytes upon C/EBP-b inhibition by a pool of spe-
cific siRNAs, in presence or absence of IL-17A treatment.
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4.4.4 miR-378a promotes inflammation through upregulation of 
the IL-17A-related chemokines IL-8/CXCL8 and CCL20
To investigate the effect of miR-378a overexpression in cultured keratinocytes, we 
transiently transfected monolayers of primary human keratinocytes with miR-378a 
mimics or control mimics, followed by adding or not IL-17A, and continued the 
treatment for 24 hours. The samples served for microarray transcriptomic profil-
ing, which principal component analysis (PCA) has shown separation of the four 
groups including keratinocytes transfected with miR-378a mimics (with or with-
out IL-17A treatment) as well as with control mimics (with or without IL-17A 
treatment) (Figure 32a). In the absence of IL-17A, 266 genes were significantly 
deregulated upon overexpression of miR-378a (186 were up- and 80 were down-
regulated) (Figure 32b-left). In the presence of IL-17A, 194 genes were found 
significantly differentially expressed by miR-378a overexpression (127 genes were 
up- and 67 downregulated) (Figure 32b-right). Gene ontology pathway analysis 
have shown the implication of these genes in biological processes related to skin 
development, epidermal differentiation and cytokines (in particular IL-6)-mediated 
signaling pathways. We could observe a significant increase in the expression of 
pro-inflammatory cytokines CXCL8/IL-8 and CCL20 by overexpressing miR-378a 
(Figure 32c), while a reduction in their expression levels was detected upon inhibi-
tion of miR-378a (Figure 32d). Given that these cytokines are typically released by 
triggered keratinocytes during inflammatory events occurring in psoriasis lesions 
[34, 38, 126, 127], the results obtained are in line with the up-regulation of miR-
378a found in psoriatic keratinocytes.
78
Figure 32. (a) PCA performed on microarray data obtained from treating cultured keratino-
cytes with oligo controls only (blue) and in presence of IL-17A (gray) or miR-378a mimic 
only (yellow) and in presence of IL-17A (red). (b) Volcano plot showing the proportion of 
differentially expressed transcripts detected by the microarray gene expression profiling 
in miR-378a mimic vs mimic control in absence (left) and presence (right) of IL-17A. Red 
dots represent down-regulated genes (FC <0.67); red dots the up-regulated genes (FC 
>1.5). (c) RT-qPCR analysis of CXCL8/IL-8 and CCL20 expression in cultured keratino-
cytes transfected with miR-378a mimic or mimic control, in presence or absence of IL-17A. 
(d) RT-qPCR analysis of CXCL8/IL-8 and CCL20 expression in cultured keratinocytes 
transfected with miR-378a inhibitor or inhibitor control, in presence or absence of IL-17A.
4.4.5 miR-378a suppresses the NF-kB-inhibitor NFKBIA
The transcription factor NF-kB plays an essential role in orchestrating the expres-
sion of genes coding for pro-inflammatory molecular mediators such as cytokines, 
chemokines and growth factors in human diseases [503-505]. In psoriasis, it is 
known to control inflammatory processes, as well as proliferation, differentiation 
and death for apoptosis of keratinocytes [506]. NF-kB is kept inactive in the cyto-
plasm by the IkB (inhibitor of kappa-B) protein family [507] and able to exert its 
function upon translocation into the nucleus after IkB proteins get phosphorylated 
by a class of kinases named IKK (inhibitor of kappa-B kinase) [508].
To refine the mechanism through which miR-378a overexpression could promote 
inflammation in psoriatic keratinocytes, we studied its predicted targets. These 
were found using the online tool TargetScan [509], by identifying the presence of 
conserved sites on mRNAs that match the seed region of miR-378a. Among these, 
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we have found NFKBIA (IκBa) as one of the most interesting, since involved in 
the interruption of the nuclear translocation signals of NF-kB, holding it inactive 
in the cell cytoplasm [510, 511]. In addition, NFKBIA is also known to regulate 
inflammatory processes in skin diseases [512]. Due to the complementarity between 
miR-378a seed-sequence and the 3’UTR of NFKBIA (Figure 33a), we investi-
gated whether inhibition or overexpression of miR-378a would have affected the 
expression of NFKBIA protein. As expected, we have seen a reduction in NFKBIA 
protein production when miR-378a was up-regulated in cultured keratinocyte, as 
well as an increased expression when miR-378a was knocked down (Figure 33b).
Figure 33. (a) Illustration of the 8-mer predicted complementarity between miR-378a seed 
sequence and 3’UTR of NFKBIA gene. (b) western blot analysis showing the effects of 
miR-378a inhibition and overexpression in cultured keratinocytes on the NFKBIA protein 
production.
Taken together, our results unfolded the importance of miR-378a in psoriasis-
associated events, enhancing inflammation through the promotion of cytokines 
and chemokines expression in psoriatic keratinocytes, as well as by stimulating 
epidermal cells proliferation, which results in thicker skin.
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5 CONCLUSIONS AND FUTURE 
PERSPECTIVES
Psoriasis has dramatic implications on the quality of life of about 125 million 
people worldwide. Despite the remarkable number of gene expression profiling 
studies attempting to clarify the impact of genomic alterations in the pathogenesis 
of psoriasis, the majority of these were performed without discerning specific cell 
populations in the skin. While aware of an altered cross-talk between keratinocytes 
and immune cells in psoriasis, the goal of this thesis was to gain a deeper under-
standing of the keratinocyte-specific transcriptomic changes in psoriasis lesional 
and non-lesional skin.
In our first study, we identified more than 2,000 protein-coding genes with sig-
nificantly altered expression in psoriasis lesional keratinocytes compared to 
keratinocytes from healthy skin (study I). The most up-regulated genes were 
enriched for pathways related to innate immunity, cell proliferation and inflam-
mation. This was consistent with previous profiling studies using full-depth skin 
biopsies. Type I interferon and NF-kB were enriched among our set of deregulated 
genes in psoriatic keratinocytes compared to healthy skin, again in line with previ-
ous studies. Interestingly, we have also found a set of genes, for example TNIP3 
(TNFAIP3 Interacting Protein 3) and TNFAIP3 (TNF Alpha Induced Protein 3), 
which were previously believed to be expressed by immune cells. We validated 
the overexpression of the previously uncharacterized gene EPGN, a growth factor 
that promotes keratinocytes proliferation and therefore potentially contributing 
to epidermal hyperplasia in psoriasis. Among the down-regulated genes in pso-
riatic keratinocytes, epidermis development and differentiation were pathways 
enriched, explaining the alteration of these processes in psoriasis. GSEA analysis 
using cytokine-induced gene signatures confirmed the important role of IL-17 and 
IL-22 signatures on the gene expression changes found in keratinocytes from the 
psoriasis lesions. Surprisingly, approximately 50% of the overexpressed genes 
in psoriatic keratinocytes did not overlap with cytokine-induced gene signatures, 
suggesting intrinsic alterations of the keratinocyte transcriptome. Therefore, we 
focused on potential genetic aspects of psoriasis. We have found a large share of 
differentially expressed genes in keratinocytes from psoriasis lesion compared to 
healthy skin overlapping SNPs associated to psoriasis susceptibility by previous 
GWAS studies. Many of them were localized in proximity or overlapping the 
epidermal differentiation complex (EDC) on chromosome 1, where PSORS4 is 
also located. These findings suggest that a part of the gene expression changes 
in psoriatic keratinocytes could be explained by genetic variation, contributing 
– together with immune cell functions – to the psoriasis susceptibility. We also 
analyzed the expression of transcription factors in psoriasis keratinocytes and iden-
tified 54 transcription factors had altered expression, including previously known 
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in the psoriasis context such as AP-1, RORA, SOX4, KLF4, NF-kB, EGR and 
GATA3, some of which are located on psoriasis-susceptibility regions, supporting 
the link between genetic susceptibility and keratinocytes transcriptomic alterations 
in psoriasis. Other altered transcription factors identified in our study, including 
TRPS1, HEY2 and PAX3, were uncharacterized in the context of psoriasis and 
their role in the disease will need further study. Interestingly, several genes were 
found differentially expressed in psoriasis non-lesional compared to healthy epi-
dermal cells, suggesting that keratinocytes contribute to the “pre-psoriatic state” 
of non-involved skin in psoriasis patients.
In study II, we investigated the expression of non-protein coding RNAs in the 
epidermal cells (CD45-negative cells) of patients with psoriasis, with a focus on 
the long intergenic non-coding RNA class. More than 450 deregulated non-coding 
transcripts were found in our analysis. In psoriatic keratinocytes, we have confirmed 
the overexpression of PRINS, the first lncRNA found altered in full-depth skin 
biopsies from psoriasis patients, as well as identified previously uncharacterized 
lncRNAs, e.g. NEAT1, which expression was not found significantly altered in 
other psoriasis transcriptomic studies using full-depth skin biopsies. We validated 
the expression of the lncRNA LINC00958, which was upregulated in keratinocytes 
from psoriasis lesion compared to both psoriasis non-lesion and healthy keratino-
cytes. This lincRNA has been described in several cancers affecting different 
organs but it has not been previously identified in psoriasis. Besides confirming 
its non-coding potential, we have also determined its expression in different skin 
cell types, excluding the possibility that the overexpression we observe in psoria-
sis lesions is attributable to dermal or immune cell components. The cytoplasmic 
enrichment of LINC00958 opens new possibilities for future experiments aiming 
to further characterize this lncRNA in the context of psoriasis. Functional stud-
ies are needed to shed light on its function in the disease, which according to 
its subcellular localization we could expect to be controlling mRNA stability or 
regulating mRNA translation. 
Similar to mRNAs, the majority of the changes in non-coding transcripts expres-
sion were detectable comparing psoriatic lesional keratinocytes with healthy 
skin. However, changes in the expression of several lincRNAs were found also in 
uninvolved non-lesional keratinocytes of psoriasis patients compared to healthy 
skin. These alterations in the keratinocytes-specific non-coding transcriptome sug-
gests a situation of “pre-psoriatic inflammatory stage” occurring in psoriasis non-
lesional epidermis. Interestingly, a part of the differentially expressed non-coding 
RNAs were overlapping with psoriasis-associated genetic loci on chromosome 
1 (PSORS4, epidermal differentiation complex regions), and on chromosome 6 
(PSORS1, psoriasis risk allele HLA-C*06:02), suggesting the contribution of 
lncRNAs to the genetic susceptibility to psoriasis.
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In study III, we aimed to investigate the potential of circulating miRNAs to 
become a diagnostic tool to use in clinical practice that could overcome the chal-
lenges of an early diagnosis of psoriatic arthritis manifestations, in patients with 
cutaneous psoriasis. We investigated whether changes in the expression levels of 
circulating microRNAs in extracellular vesicles could serve as biomarkers for this 
purpose. A cohort including patients with cutaneous-only psoriasis since ten years 
and patients with confirmed psoriatic arthritis upon ten years follow-up, was used 
for small RNA-sequencing profiling screening. This revealed microRNAs with 
altered expression levels in plasma extracellular vesicles. Some of the discovered 
miRNAs were included in the following validation phase and quantitative real-time 
PCR analysis confirmed the down-regulation of the miRNAs let-7b-5p and miR-
30e-5p in patients with confirmed arthritis manifestations and cutaneous psoriasis 
compared with patients with cutaneous psoriasis only. Let-7b-5p, which has been 
associated to inflammatory events in atherosclerosis, directly targets IL-6, a pro-
inflammatory cytokine overexpressed in patients with psoriatic arthritis compared 
to patients with cutaneous-only psoriasis, and other genes associated to joint inflam-
mation (HMGA1 and HMGA2) or inflammatory bone loss (PRDM1). The level 
of miR-30e-5p in extracellular vesicles was found reduced in a study comparing 
PBMC from patients affected by rheumatoid arthritis with those from healthy 
donors. Down-regulation of miR-30e-5p leads to increased expression of its target 
BMI1, mediator of arthritis in mice through the activation of the NF-kB signaling 
pathway. Limitations encountered in our study, which are common in these type 
of exploratory profiling studies, include the relatively small sample size within the 
two cohorts, as well as the technical and biological variability for example across 
the samples. However, a strength of this study is that patients did not receive any 
systemic treatments and, thus, we excluded the potential effect of systemic treat-
ments on circulating miRNAs. Another strength is the use of extracellular vesicles 
instead of whole plasma. Since miRNAs are secreted selectively into EVs, these 
may therefore be more specific markers than those from whole plasma. Future 
studies on larger cohorts of patients would definitely provide more insights about 
the potential of these miRNAs as diagnostic tools for psoriatic arthritis.
In study IV we aimed to characterize functionally the miRNA miR-378a in pso-
riasis. Small RNA sequencing analysis of CD45-negative cells from psoriasis 
lesion/non-lesion and healthy skin performed by our group, identified miR-378a 
to be overexpressed in psoriasis lesional keratinocytes. Once more, this approach 
helped avoiding potential miRNA expression signature “contaminations”, coming 
from dermal cells or immune cells infiltrating the epidermis of psoriasis patients. 
As a model of psoriasis-like skin inflammation, we applied imiquimod (Aldara®) 
cream on shaved back skin of mice, which histologically and at the molecular level 
resembles human psoriasis. Injection of miR-378a into mouse skin together with 
induction of skin inflammation increased overall skin thickness, the number of 
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proliferating cells in the basal layer of the epidermis and increased the expression 
of the pro-inflammatory chemokines and cytokines Cxcl1, Ccl20 and Il-17c. These 
results suggested that miR-378a actively participates in establishing inflammatory 
processes in the skin. We have also found that IL-17A can increase the expression 
of miR-378a in cultured primary human keratinocytes. Studying the alterations in 
its expression upon interruption of the IL-17A-related pathways NF-kB and C/EBP-
b, we have confirmed the importance of these transcription factors in establishing 
an inflammatory response through the action of miR-378a. Next, we performed 
Gene Ontology (GO) Biological Processes (BP) pathway analysis of genes differ-
entially expressed upon miR-378a-overexpression and inhibition. Enrichment in 
skin development, regulation of epidermal differentiation, cytokines- and, specifi-
cally, IL-6-mediated signaling pathway were found among the genes regulated by 
miR-378a. In addition, inflammatory cytokines including IL-8/CXCL8 and CCL20 
underwent enhanced expression in cultured primary human keratinocytes when 
miR-378a overexpression by mimic transfection was combined with IL-17A treat-
ment. At last, upon miR-378a overexpression we have detected reduced NFKBIA 
protein expression, a predicted direct target of miR-378a which regulates the acti-
vation, and further translocation to the nucleus, of NF-kB. We hypothesize that this 
could explain the mechanism through which miR-378a boosts the inflammation 
through the previously described psoriasis-associated cytokines. Further studies 
on the phosphorylation of NF-kB upon miR-378a inhibition/overexpression will 
reveal the genuine answer to this question.
Overall, our studies identified specific transcriptomic changes in keratinocytes 
from psoriasis lesional and non-lesional skin. These included both coding and non-
coding genes, complementing previous profiling studies in psoriasis and further 
highlighting the contribution of keratinocytes to molecular changes in the disease, 
in part genetically determined (intrinsic) and in part sustained by cytokines-related 
inflammatory processes (extrinsic). Future functional studies of the coding and 
non-coding transcripts, as well as the microRNAs, found deregulated in the epi-
dermis of psoriasis lesions could reveal their role in skin-related processes, such 
as the maintenance of epidermal homeostasis, as well as in impairing keratinocyte-
related functions in psoriasis. Furthermore, we have identified two microRNAs, 
let-7b-5p and miR-30e-5p, which require additional studies in larger cohorts in 
order to be established in clinical practice routines, for the diagnosis of early 
arthritis manifestations in patients with cutaneous psoriasis.
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